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Huajia Zhang 
FUNCTIONAL ROLE OF THE TLR4 SIGNALING PATHWAY IN THE BONE 
MARROW RESPONSE TO SEPSIS 
Sepsis is a clinical syndrome due to a systemic inflammatory response to 
severe microbial infection. Little is known about the changes in the bone marrow 
(BM) and how they affect the hematopoietic response to bacterial infection. Using 
an animal model of severe sepsis induced by Pseudomonas aeruginosa, we 
have previously reported that hematopoietic stem cells (HSC) undergo a 
significant expansion in the BM accompanied with myeloid suppression. This 
bone marrow response was Toll-like Receptor 4 (TLR4)-dependent. TLR4 is 
activated by bacterial lipopolysaccharide (LPS) and signals through two major 
independent downstream molecules: TRIF and MyD88. In the present study, I 
found that the TLR4/TRIF and the TLR4/MyD88 pathways contribute in a distinct 
manner to the BM response to P. aeruginosa’s LPS. TRIF plays a major role in 
the expansion of the HSC pool, whereas MyD88 is required for myeloid 
suppression. Following LPS stimulation, HSCs enter in the cell cycle, expand and 
exhaust when transplanted in healthy mice. Loss of TRIF rescued completely the 
long-term engraftment and multilineage reconstitution potential of septic HSCs, 
but did not affect myeloid differentiation. Conversely, MyD88 deficiency 
prevented completely the myeloid suppression in the myeloid progenitors, but 
conferred limited protective effects on the HSC function.  
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It is of great therapeutic value to identify the downstream molecules 
involved in TLR4/MyD88 dependent myeloid suppression. I found miR-21, a 
microRNA that is involved in inflammation, was up-regulated upon LPS challenge 
in a MyD88-dependent manner. However, deletion of miR-21 in the BM did not 
rescue LPS-induced bone marrow dysfunction, demonstrating that miR-21 is not 
a critical regulator in these processes. Further studies are warranted to 
determine the precise molecular mechanisms involved in the complex 
pathogenesis of BM response to sepsis. Taken together, my results show for the 
first time that the TLR4/TRIF signaling as a key mediator of HSC damage during 
acute LPS exposure and that activation of the TLR4/MyD88 signaling pathway 
play a dominant role in myeloid suppression. These results provide novel insights 
into our understanding of the molecular mechanisms underlying bone marrow 
injury during severe sepsis and may lead to the development of new therapeutic 
approaches in this disease. 
 
                                                                                   Nadia Carlesso, M.D., Ph.D. 
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CHAPTER ONE 
INTRODUCTION 
SEPSIS  
Sepsis is defined as Systemic Inflammatory Response Syndrome (SIRS) 
induced by pathogen infections [1,2]. The SIRS criteria were first put forth by the 
American College of Chest Physicians/Society of Critical Care Medicine 
Consensus Conference in 1992, and include two or more of the following 
symptoms: 1) Body temperature > 38 oC or < 36 oC; 2) Heart rate > 90 beats per 
minute; 3) Respiratory rate > 20 breaths per minute or arterial CO2 tension less 
than 32mmHg; and 4) white blood cell count greater than 12,000/mm3 or less 
than 4000/mm3 [3]. Severe sepsis develops when one or more organ system 
become dysfunctional upon the onset of infection-related SIRS. Septic shock is 
severe sepsis accompanied by hypotension [4].  A recent study revealed that 
gram-negative bacteria accounts for the majority (62%) of infections in intensive 
care units worldwide [5].   
Despite the long history of the battle between sepsis and human [2], the 
prevalence and incidence of the disease remains high, especially in emergency 
rooms and intensive care units [6]. Listed as the 11th leading cause of death in 
the United States in 2009 by the Centers for Disease Control and Prevention [7], 
severe sepsis was recently estimated to cost over twenty billion dollars annually 
to the U.S. health care system [8]. In the developed world, the rate of sepsis 
climbs annually due to increased aging population and the development of 
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antibiotic-resistant bacterial infections. In the developing countries, malnutrition, 
poverty, poor hygiene conditions and lack of timely treatment contributes to high 
incidence of sepsis. The difficulty in managing sepsis lies mainly on the high level 
of heterogeneity of the disease. For instance, pathogens, affected organs and 
the time of intervention for each individual patient can be different and require 
distinct therapeutic strategies. Cardiovascular, respiratory and renal dysfunctions 
were found to be the most common affected organ systems in sepsis [9-12]. 
While concerted efforts are ongoing to elucidate the molecular and cellular 
mechanism underlying the dysfunctional alterations in these organ systems, 
limited progress has been made on the study of sepsis induced alterations in the 
bone marrow (BM). The BM is poised to respond quickly to local changes elicited 
by trauma or inflammation. In fact, it was not until recently when the BM,  where 
most immune cells derive from, was studied as one of the organs that is also 
dramatically affected by sepsis and inflammation [13]. The study of BM response 
during sepsis will provide further therapeutic opportunities to improve the 
prognosis and survival of patients with sepsis.  
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ANIMAL MODEL OF SEPSIS 
Rodent models provide a significant tool for studying sepsis pathology 
while satisfying reproducibility and consistency. The sepsis model can be divided 
into three categories: 1) endotoxin administration; 2) bacterial inoculum model 
and 3) fecal pellet mode [14-17].  
Endotoxin administration 
Systemic administration of endotoxin can be also referred to as the LPS 
(Lipopolysaccharide) model [17]. LPS or endotoxins were first identified in 1941 
by Andre Boivin [18], and are glycolipids found in the cell wall of gram-negative 
bacteria [19]. LPS can initiate innate immune response in affected individuals 
mainly through the Toll-like Receptor (TLR) pathways [20]. Previous studies have 
shown that low dose injection into healthy volunteers triggered 
pathophysiological changes similar to septic patients [21,22]. The LPS model is 
usually performed with intraperitoneal (i.p.) or intravenous (i.v.) infusion into the 
animal. It can induce a series of septic events observed in human, such as 
hematological alterations and increase of pro-inflammatory cytokines in the 
serum [23]. The LPS model provides a simple and reproducible way to determine 
many pathophysiology changes during sepsis. Compared to other sepsis models, 
it is easier to tightly control the experimental system with the use of specific strain 
and dose of the endotoxins [16]. Experimental data generated from endotoxin 
models are usually more reproducible and consistent between different 
independent groups due to the simplicity of the experimental process [23]. The 
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caveat of the LPS model is that it does not always reflect key events that occur in 
septic patients. For instance, cytokine levels peaked in a prolong manner and at 
a lower levels in the septic patients while LPS-infusion led to a transient and high 
levels of cytokine production in animal models [24]. The endotoxin model was 
first developed based on the hypothesis that endotoxin is the key component that 
trigger septic shock in patients, which was later discovered not true in multiple 
studies [25]. In fact, the level of endotoxin discovered in septic patients is 
frequently lower than the dose administered to the experimental animals [26]. 
This also may explain the failure of several therapeutic trials aiming to block or 
eliminate the endotoxins in septic patients [27]. The endotoxin model does not 
represent the complexity of the actual disease where more than one pathogen 
can be present and are replicating within the host. In short, one need to be 
mindful when incorporating findings from the endotoxin models into testing the 
efficiency of therapeutic interventions and into treatment recommendations for 
patients. Despite the limitations, the LPS model is no doubt a valuable tool for 
identifying the cellular and molecular mechanisms of many septic pathological 
events during the early stage of research.  
Bacterial inoculum model 
The bacterial inoculum model is generated via intravenous administration 
of concentrated live pathogen organisms into the recipient animal. Besides 
rodents, bacteremia model animals also include non-human primates, canine 
and swine [28-37]. It has been criticized that the bacterial inoculum model does 
not mimic human sepsis. Host animals are usually infused with a high dose of 
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live bacteria at one time whereas in human sepsis, patients are not exposed to 
such massive loads of pathogens. As Wichterman et al. noted, septic patients 
usually harbor a septic focus which is intermittently, but persistently, showering 
the body with bacteria [18]. Another caveat of this model is that the complement 
response could lead to rapid lysis of the high doses of bacteria administered and 
prevent them from colonizing and replicating within the host, leading the model to 
somewhat become an endotoxin model rather than a true model of infection [38]. 
Finally, there are several factors that could significantly interfere with the host 
response such as bacterial load, bacteria strain specificity, and route of infection 
among others [16]. It is of great importance to limit the variables when performing 
experiments and to consider these variables when interpreting and comparing 
results generated from other groups to one’s study. Despite the inherent 
limitations of the bacterial inoculum models, they remain a useful tool to unravel 
the mechanisms of the host response during sepsis.  
Fecal pellet model 
Well-known as a gold-standard model for polymicrobial sepsis, the cecal 
ligation and puncture model (CLP) has been extensively used for more than 
three decades since its development by the Chaudry group [18,27,39]. The CLP 
technique involves creating fecal leakage from the normal protective barriers of 
the caecum distal. It is a model induced by peritoneal contamination by the 
microflora from the gut of the animals. This model achieves its popularity 
because of the following advantages. First, it is simple to perform. Instead of 
growing high concentration of bacteria prior to bacterial inoculum, the CLP model 
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only requires a straightforward surgical procedure [27]. Second, the ability of the 
CLP model to recapitulate the human disease progression is very attractive for 
therapeutic development. For instance, the CLP model can reproduce a 
hemodynamic profile and cytokine elevation pattern similar to the actual disease 
[27,31,39]. While the other sepsis models allow for the study of septic response 
to one particular pathogen or endotoxin, the CLP model creates a condition that 
is induced by polymicrobial infection, which is more often the real situation in 
septic patients. Finally, this model has good versatility. By adjusting the size of 
needle, the number of punctures (one-hit or two-hit), and the location of the 
puncture, one can induce a wide spectrum of sepsis severity, ranging from 
chronic and moderate to acute and lethal [31]. However, there is no perfect 
model in this research field, as the CLP model has its own caveats. Disparities in 
results derived from CLP model in different laboratories have been the most 
significant limitation noted in the model [40]. Such discoveries could be due to 
several factors: 1) surgical operator variability; 2) different anesthetic agents 
used; 3) animal housing condition; 4) gut flora differences from distinct mice 
strains [16,18,21,39,40]. Unlike the LPS model, it is very difficult to control the 
magnitude of the septic challenge induced by the CLP model; therefore, results 
generated from this model can have a significant variability. One way to 
overcome the variability is to increase the sample size, especially in small 
animals. The Chaudry group has proposed the criteria for a model of sepsis: 1) 
The mice should be toxic and have positive blood cultures; 2) it should manifest 
true characteristic metabolic and physiologic perturbations; 3) the septic insult 
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should occur over time and; 4) it should be reproducible and inexpensive [32]. 
The CLP model fulfills a lot of the criteria for a biologically relevant sepsis model.  
Since there is not one sepsis model that can completely recapitulate the 
human disease with good standardization, reproducibility and versatility, it is 
important to select the right model suitable for solving the research problem. The 
current project is a further pursuit of the work published from the Carlesso group. 
In the previous research, burn and inoculation of Pseudomonas Aeruginosa was 
performed in a mouse model [13]. Our group has previously found that the i.p. 
injection of P. aeruginosa’s LPS was able to recreate the hematological and BM 
response observed in the bacteremia model. Therefore, it is plausible that the 
LPS model can be used as a simplified tool to study the cellular and molecular 
mechanism underlying the BM response during P. aeruginosa sepsis. 
Furthermore, I also introduced the CLP model in my current study to demonstrate 
that similar BM pathological alterations were also found in polymicrobial sepsis.  
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PATHOGENESIS OF SEPSIS 
SIRS, CARS or MARS 
In 1972, Lewis Thomas proposed an innovative theory about infectious 
disease. He stated that instead of the pathogens being viral, it was our 
hyperactive immune response that do harm to ourselves and trigger lethal events 
such as organ injury [41].  A considerable amount of findings support this theory. 
Tumor necrosis factor alpha (TNF-α) was the first inflammatory cytokine 
identified to indicate poor prognosis outcome for septic patients [42,43]. 
Interleukin 1 (IL-1) was found to induce similar inflammatory response such as 
TNF-α [44]. Both IL-1 and TNF-α are able to activate target cells such as 
endothelial cells, macrophages, neutrophils and monocytes to produce more 
inflammatory mediators, leading to amplification of the inflammatory signal 
[22,45,46]. More cytokines were later found to be involved and increased during 
SIRS, such as IL-6, IL-8, IL-12 and interferon gamma (IFN-γ) [22,47,48]. 
Simultaneously, the complement system is activated, leading to C5a production, 
which is able to further enhance cytokine and chemokine production [49]. The 
normal function of the coagulation system is also hampered during SIRS, with 
formation of blood clots and reduction of blood flow. Frequently in septic patients 
intravascular disseminated coagulation occurs, leading to ischemic injury to 
organs and tissues, which is associated often with organ failure [50,51]. 
Coagulation disorder in sepsis is due to the failure to generate adequate 
Activated Protein C (APC), a proteolytic inhibitor of clotting factors. Besides 
regulating normal coagulation, APC can also inhibit TNF-α, IL-1 and IL-6 
9 
 
production from monocytes. Reduced APC activity therefore promotes the 
expansion of the pro-inflammatory status [52,53]. At this point, the body of the 
septic patient is showered with high level of pro-inflammatory cytokines, 
chemokines, and acute phase protein. These mediators activate phagocytic cells 
(neutrophils and macrophages) to release granular enzymes, nitric oxide (NO) 
and reactive oxygen species (ROS). These molecules are essential for pathogen 
clearance. However, excessive release of proteases and oxidants can cause 
tissue damage and lead to organ failure [1,54]. The theory that the body was 
unable to turn off the indefinitely amplifying inflammatory reaction during sepsis 
led to numerous trials aiming at attenuating the effects of pro-inflammatory 
mediators. Most of these studies, unfortunately, were not successful in improving 
patient survival. Although two independent groups have found that TNF-α 
blockade protected mice and baboons from endotoxic shock or bacteremia, no 
survival benefits in human patients were found in subsequent clinical trials [55-
57]. Similarly, inhibition of IL-1 through recombinant IL-1 receptor antagonist did 
not confer protective effects in human patients even though it reduced the 
mortality rate in animal models [58,59]. One explanation for the different results 
found in human and animal model is that the cytokine production pattern is 
different, being prolonged and accumulative in human patients while transient 
and dramatic in animal. Therefore, after multiple trials examining the efficacy of 
counteracting pro-inflammatory mediators turned futile, researchers start to 
reconsider Lewis Thomas’ theory.     
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Roger Bone was a pioneer researcher in sepsis who first put forth the term 
compensatory anti-inflammatory response syndrome (CARS). He pointed out 
that Lewis Thomas’ theory was one-sided; it overlooked the anti-inflammatory 
response that was also incited in response to the inciting event [60]. It is now 
known that the host response to sepsis involves not only immune stimulation but 
also immunosuppression. Several reviews stated that as sepsis progress, CARS 
become predominant. Anti-inflammatory mediators such as IL-4, IL-10, 
transforming growth factor-β (TGF-β) and granulocyte colony-stimulating factor 
(G-CSF) are produced. T-cell anergy occurs at the same time and Th2 cell (anti-
inflammatory) differentiation is favored [61]. Apoptosis in B cells becomes 
prevalent [62]. Neutropenia, one of the poor prognosis factors for patient survival, 
is commonly found in CARS. Immune paralysis renders sepsis patients even 
more vulnerable to secondary infection and is associated with lethality [63]. One 
study found reduced TNF-α and IL-6 production in intensive care units (ICU) 
patients [64]. Another group found that patients with severe burns and sepsis 
exhibit T cell proliferation and fail to produce IL-2 and IL-12 [65,66]. Based on 
these results, therapeutic interventions trying to boost the suppressed immune 
system were examined.  Administration of stimulation agents such as G-CSF and 
granulocyte macrophage colony-stimulating factor (GM-CSF) to sepsis patients, 
however, showed no improvement in survival [67]. The difficulty in finding a 
magic bullet to cure this complex disease lies greatly in the heterogeneity of a 
patient’s immune status. Roger Bone proposed a delicate summary of the 
interaction between SIRS and CARS: if pro-inflammatory and anti-inflammatory 
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responses balance each other locally, then homeostasis is restored; otherwise 
either pro-inflammatory or anti-inflammatory mediators will spill over to the 
circulation system and render the patients either SIRS or CARS. Many times, a 
heterogeneous pattern of SIRS and CARS can occur simultaneously and the 
patients will suffer from the mixed antagonistic response syndrome (MARS) 
[60,68]. In summary, it is now generally accepted that the pathology of sepsis is 
the failure to maintain a homeostatic balance between hyperactive and 
inadequate inflammation. Therefore, accurate diagnosis of the stages of SIRS 
and CARS is essential for providing the proper medical intervention for each 
individual septic patient.  
Cellular responses during sepsis  
Cellular dysfunctional changes in sepsis can be divided into two groups: 
excessive activation and depressed function [4]. The cellular component of the 
sepsis response includes phagocytes (neutrophils and monocytes) and  
lymphocytes (T, B, NK cell) [46].  
Neutrophils are a critical component of the innate immune response. They 
are the primary effector cells for pathogen clearance. Originated from the 
hematopoietic stem and progenitor cells in the BM, neutrophils are released into 
the circulation system with a short lifespan of 5.4 days in human under normal 
conditions [69]. The mobilization of neutrophils is mainly directed by G-CSF and 
GM-CSF [70]. Circulating neutrophils move along the blood vessel luminal 
surface through low-affinity interaction between L-selectin/CD62L on the 
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neutrophils and E-/P- selectin (CD62E/CD62P) on the endothelium [71]. When 
inflammation occurs, inflammatory regulators stimulate the expression of β-
integrins on the surface of neutrophils, which then bind intensively with ICAM-
1/CD54 and VCAM-1/CD106 on the endothelial cells, facilitating firm adhesion of 
neutrophils to the endothelium near the infected site [72]. Adherent neutrophils 
then transmigrate through the tight junction of the endothelium along a gradient 
of chemokines, complement factors and chemoattractant, for example; these 
factors finally guide the neutrophils to the site of infection to perform their 
phagocytosis function for pathogen clearance [73]. Besides phagocytosis, 
neutrophils also release antimicrobial products such as protease enzymes, 
oxygen radicals and NO. Robust and appropriate function of neutrophils is crucial 
for an effective functional innate immune response. During sepsis, however, 
neutrophils often become either hyperactive or defective, both leading to 
destructive outcomes. Pro-inflammatory signals can extend the half-life of 
neutrophils in the circulation by delaying apoptosis, leading to overly exuberant 
neutrophil activation [70,74]. Excessive production of antimicrobial products such 
as proteolytic enzymes initiates local tissue injury, which ultimately can develop 
into organ failure [14,71]. In septic patients that are immunosuppressed, blunted 
neutrophil function renders them more vulnerable to secondary infections [75]. It 
has been found that neutrophils from septic patients have increased expression 
of integrins on the surface, augmenting the intensity of endothelium adherence 
but lowering the ability to transmigrate into the infection sites [71]. Neutropenia is 
a common poor prognosis factor and is associated with high mortality rate [13]. 
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Neutrophils are a double-edged sword in the pathogenesis of sepsis. The fact 
that neutrophil functions are over active in some patients while suppressed in 
others demonstrates the heterogeneous nature of sepsis. Just as a homeostatic 
balance between pro-inflammatory response and anti-inflammatory response is 
of crucial importance for a proper host response, a tight regulation of neutrophil 
activity is also of great importance to prevent tissue injury and infectious 
complications.  
Lymphocytes include T cells, B cells and NK cells. T and B cells are 
required for adaptive immune response while NK cells are effectors in the innate 
immunity.  Systemic apoptosis of lymphocytes has been reported in septic 
patients infected with P. aeruginosa [62,76]. Massive depletion of CD4, CD8, B 
cells as well as of dendritic cells were found in septic patients who died in the 
ICU [63,77]. CD4+ T cells can differentiate into either pro-inflammatory type 1 
helper Th1 cells or anti-inflammatory Th2 cells. Th2 cells have anti-inflammatory 
properties and are predominant in the blood of septic patients with burns or 
trauma [66]. T cell anergy is another cellular mechanism that contributes to 
immune paralysis, as T cells become nonresponsive to specific antigens. Anergic 
T cells neither proliferate nor produce cytokines in response to cognate antigens. 
In summary, T and B cells depletion, T cell anergy and Th2 dominance are key 
cellular mechanisms underlying adaptive immune response suppression during 
sepsis.  
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Endotoxin and Toll-Like receptor 4 
More than 60% of infections in the ICU worldwide are due to gram-
negative bacteria [5]. As early as 1892, Pfeiffer et al. have found that a heat-
stable material associated with gram-negative bacteria was able to induce shock 
and death in animals, and coined the term endotoxin [78]. Nowadays we know 
that the endotoxin is LPS, which comprise the outer leaflet of the membrane of 
gram negative bacteria. The molecular structure of LPS can be divided into Lipid 
A, the core and the O polysaccharide. Lipid A is composed of a β-D-
glucosaminyl-(1-6)-α-D-glucosamine disaccharide and is highly conserved 
among different gram-negative bacteria. It is responsible for the major toxicity of 
LPS because it can be recognized by the host’s immune cells [79]. The core 
oligosaccharide is a hetero-oligosaccharide with limited variability within different 
bacterial species. Finally, the O polysaccharide consists of repeating 
oligosaccharide units that determine the specificity of the bacteria cell wall [80].    
The hyposensitivity of C3H/HeJ and C57BL/10ScCr mice to endotoxin led 
to the identification of the TLR4 as the receptor for LPS [81,82]. The TLR4 is a 
member of the TLR family. Toll receptors were first discovered in Drosophila as a 
developmental receptor required for dorsal-ventral embryonic polarity [83,84]. 
The discovery by the Hoffmann lab that flies with Toll mutants were more 
susceptible to fungi infection first brought the awareness that this receptor is also 
important in immune responses [85]. The mammalian homologues of the Toll 
protein discovered later were then designated as the TLRs. Up to date, 10 TLRs 
in human and 13 in mice have been identified [86]. In humans, TLR3 and TLR5 
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are expressed ubiquitously. A large repertoire and variety of TLRs have been 
found in the spleen, peripheral blood leukocytes, colon, small intestine and lung, 
all tissues that are either involved in immune responses or have a direct 
counteract with microbes [87]. The location of TLR expression in mammals 
significantly reflects their biological functions. TLRs function as pattern 
recognition receptors. They are the molecular basis for immune cells to 
distinguish foreign microbial molecules (non-self) from molecules that arise from 
the host itself. During infection, TLRs interact with pathogen-associated 
molecular patterns (PAMPs) to initiate host response. The cytoplasmic domain of 
TLRs is called the Toll-Interleukin 1 Receptor (TIR) domain because it has high 
similarity with the IL-1 receptor family. The extracellular region of TLRs is 
composed of leucine-rich repeats (LRRs) [88]. The extracellular domain is 
responsible for PAMP recognition. Different TLRs can form heterodimers or 
homodimers in response to different PAMPs to activate corresponding 
inflammatory signaling pathways. For instance, TLR3 and TLR5 forms 
homodimers and recognize virus double-stranded RNA and bacterial flagellin 
respectively [89,90]. Lipoteichoic acid from Gram-positive bacteria induces potent 
immune response through interaction with TLR2 and TLR6/1 heterodimers [91]. 
TLR4 forms homodimers upon LPS ligation and is the only known TLR that is 
responsive to endotoxin [88]. 
The LPS-TLR4 interaction involves multiple acceptor proteins including 
LPS-binding protein (LBP) and CD14. A recent study showed that R-form LPS 
can activate TLR4 in a CD14-independent manner [92]. Myeloid differentiation 
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factor-2 (MD-2) forms a complex with TLR4 and is required for LPS signaling [93]. 
A study of crystal structure revealed that LPS interacts with a hydrophobic pocket 
in MD-2 and induce the homodimer formation of two copies of the TLR4/MD-
2/LPS complex [94]. LPS-induced TLR4 signaling can be mediated in a Myeloid 
Differentiation factor 88 (MyD88)-dependent and MyD88-independent manner. 
MyD88 is an adaptor protein composed of the TIR domain in the C-terminus and 
a death domain in the N-terminus. MyD88 associates with TLR4 via the TIR 
domain and upon LPS stimulation recruits IL-1 receptor-associated kinase (IRAK) 
to TLR4 through the death domain. IRAK is then phosphorylated and becomes 
activated for TNF receptor-associated factor 6 (TRAF6) recruitment, leading 
ultimately to the activation of the JNK-pathway and nuclear factor kappa B (NF-
κB) pathway. Studies with MyD88-deficient mice study revealed that besides 
TLR4, MyD88 is also an adaptor protein for TLR2, TLR5, TLR7, and TLR9. [95] 
The MyD88-independent pathway was identified when a group of genes were 
expressed in MyD88-deficient macrophages upon LPS stimulation, including 
several interferon (IFN)-inducible genes like glucocorticoid-attenuated response 
gene 16 (GARG16), immunoresponsive gene 1 (IRG1) and CXC-chemokine 
ligand 10 (CXCL10) [96]. Expression of these IFN-inducible genes was 
eliminated in TLR4-deficient macrophages, demonstrating the existence of a 
TLR4/MyD88-independent pathway. Subsequent work showed that LPS-induced 
TLR4/MyD88-independent pathway activates the transcription factor interferon 
responsive factor 3 (IRF-3) and thereby induces IFN-β, leading to the production 
of IFN-induced co-stimulatory molecules [97,98]. Laboratory mice with defective 
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TIR domain-containing adaptor (TRIF or TICAM-1) led to the discovery of the 
molecular basis for the MyD88-independent pathway. TRIF-knockout mice do not 
express IFN-inducible genes in response to LPS. Therefore, TRIF is essential for 
TLR4/MyD88-independent pathway [99-101]. Similar to MyD88, TRIF is also an 
adapter protein containing the TIR domain. Besides TLR4, TRIF also associates 
with TLR3 to induce IFN-inducible gene expression [102,103]. TRIF knockout led 
to defective TLR4-mediated cytokine production, and overexpression of TRIF in 
293T cells induced NF-κB activation [103]. Therefore, the TLR4/MyD88-
independent pathway can also induce NF-κB signaling. It is now known that the 
TLR4/MyD88 dependent pathway leads to early activation of NF-κB whereas the 
TLR4/MyD88-independent pathway induces late activation of NF-κB. Both 
MyD88 and TRIF are required for the complete activation of the TLR4 pathway 
[6,88,95]. Tight regulation of the TLR4, as well as other TLRs, is therefore of 
great importance (Figure 1.1). Inadequate TLR4 activity will hamper the host’s 
ability to clear pathogen during infection while uncontrolled activation will lead to 
immune disorder including sepsis.  
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Figure 1.1 Simplified view of the TLR4 signaling pathway. 
LPS binding to TLR4 leads to activation of the MyD88-dependent and /or MyD88-
independent (TRIF) pathway. TLR4/MyD88-dependent pathway activates p38, 
JNK and NF-κB signaling. TLR4/TRIF pathway activates delayed activation of 
NF-κB signaling and IRF-3 signaling.  
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Genomic storm 
 A recent study conducted by the Tompkins group revealed that a large 
fraction (greater than 80% of the human genome) of the leukocyte transcriptome 
was significantly changed in patients with severe blunt trauma, severe burn and 
healthy adults exposed to low-dose endotoxin [104]. This study brought about a 
new term “genomic storm”, which describes a situation where the leukocyte 
transcriptome is dramatically affected by severe injury/inflammatory stress in 
human. Results from this study demonstrated that both pro-inflammatory and 
anti-inflammatory genes were elevated in leucocytes upon the onset of injury, 
which is different from the traditional concept of SIRS/CARS. The Tompkins 
group also found a uniformed gene expression profile among patients with 
trauma, burn or healthy adults exposed to endotoxin. Interestingly, instead of 
observing that a second genomic hit was promoting poor outcomes in these 
patients, they discovered that it was the duration and magnitude of this gene 
profile alteration that was associated with detrimental complications, including 
organ failure. This novel and elegant study provides a new paradigm for sepsis 
pathogenesis at a genetic level. 
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Contribution of genetic polymorphisms to sepsis patients’ outcome 
 The genetic background of the host affects the systemic response to 
infection [105,106]. With the development of genome sequencing, single-
nucleotide polymorphisms (SNPs) in human genes are largely revealed. SNPs 
that are identified in the exon regions or intron regulatory regions of genes that 
encode proteins regulating immune responses are likely to affect the 
susceptibility and outcome of sepsis [107]. For example, SNPs in the promoter 
and coding region of the TLR4 gene are associated with higher incidence of 
gram-negative sepsis in humans and increased mortality  [108,109]. Figueroa et 
al. reported that a TLR4 polymorphism interfered with the recruitment of MyD88 
and TRIF to TLR4 upon LPS binding, which would likely affect the outcome of 
sepsis in human patients [110]. Similarly, polymorphisms in the TLR2 gene were 
reported to be associated with severe staphylococcal infections [111]. Pro-
inflammatory cytokine TNF-α played a pivotal role in the initial activation of 
inflammatory response during the early onset of sepsis. Various reports showed 
that polymorphisms of the TNF-α gene were linked to increased severity of 
inflammatory diseases such as chronic obstructive pulmonary disease and 
sepsis [112,113]. IL-6 is another highly elevated cytokine that is found in the 
serum level of sepsis patients [114]. A SNP in the promoter region for IL-6 has 
been reported to be associated with low serum level of IL-6 in premature 
neonates [115]. Genetic variations were also identified in sepsis-related 
cytokines/mediators such as IL-1 receptor antagonist (IL-1RN), IL-1β and high 
mobility group box 1 protein (HMGB1) [116-118]. Intriguingly, although  the IL-1β 
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polymorphism correlates with high secretion of IL-1β, it does not associate with 
the outcome of sepsis [116]. The variation identified in the IL-1RN is associated 
with decreased production of IL-1Ra and hence, it is hypothesized to correlate 
with increased mortality risk of severe sepsis; however, this remains to be 
established [119]. Kornblit et al. demonstrated that a genetic variant in the 
promoter region of the HMGB1 gene or a SNP in the exon region was highly 
associated with reduced long-term survival rate or increased early death 
frequency [118].  
In conclusion,  the development of the Next-generation sequencing will 
help to further identify  additional genetic polymorphisms in the coding regions of 
regulatory domains of essential mediators of sepsis, allowing for the 
development of specific personalized therapeutic strategies and accurate 
disease prognostic and diagnostic methods in sepsis.  
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INFLAMMATORY MODULATION OF HEMATOPOIESIS 
Hematopoietic Stem Cells 
 The hematopoietic stem cells (HSC) are a rare (~0.01-0.001% of total BM 
cells) population of cells with the capacity to self-renewal and to replenish the 
entire blood system [120,121]. During embryonic development in mouse, 
hematopoiesis occurs by 8 days post conception (dpc 8) in the yolk sac blood 
island [122]. Lifelong hematopoiesis depends on the yolk sac HSC, which not 
only provide local hematopoiesis during development but also is the root of 
hematopoiesis in the BM and spleen [123].  
 In the past 20 years, advances in flow cytometry, in vitro colony assays 
and in vivo reconstitution assays have led to the identification and purification of 
murine HSC, as well as of their progenies [121,124]. In 1988, Spangrude et al. 
enriched a fraction of the mouse BM cells that were able to rescue 50% of 
lethally irradiated mice, when injected via tail vein. This fraction was identified as 
Lineage marker (Lin; including TER119, Mac1, Gr1, CD45R/B220, CD3, CD4, 
CD8)-Thy-1.1LowSca-1+ [125]. In 1991, the Ogawa group found that the 
multilineage reconstitution ability of the mouse BM cells was exclusive to the 
cells expressing a receptor for stem cell factor (SCF) named c-Kit [126]. The LSK 
(Lin-Sca-1+c-Kit+) fraction have since then become the canonical marker for 
hematopoietic stem cell enrichment [127]. It was later recognized that the LSK is 
a heterogeneous population that encompasses long-term HSC (LT-HSC), short-
term HSC (ST-HSC) and multipotent progenitors (MPP) [127-129]. The LT-HSC 
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are the most primitive HSC with the capacity to self-renewal and life-long 
reconstitution. The LT-HSC make up only about 10% of the LSK fraction [121]. 
The ST-HSC, on the other hand, can provide transient reconstitution in lethally 
irradiated recipients and sustain self-renewal capacity for about 8 weeks [127]. 
The identification of the signaling lymphocytic activation molecule (SLAM) family 
proteins allowed further discrimination of the various populations within the LSK 
fraction. Morrison et al. demonstrated that LT-HSC highly express the SLAM 
marker CD150, but not CD48. The expression levels of CD48 increases as HSC 
differentiate into less primitive populations (ST-HSC and MPP). A simple gating 
of CD150+CD48- within the LSK fraction could enrich LT-HSC to about 1 in 2 
cells [130]. High degree of LT-HSC purity could also be achieved using the 
gating criteria of Lin-Sca-1+c-Kit+CD34-Flt3- [128,131,132]. An alternative strategy 
utilized the HSC’s characteristic of effluxing the Hoechst 33342 dye, which 
identified the side population (SP) in combination with the LSK markers as the 
LT-HSC [133-135].  
A clear-cut phenotypic definition of the ST-HSC and MPP remain to be 
proposed. Multiple models have been proposed regarding the differentiation 
hierarchy. Akashi et al. suggested that the ST-HSC and MPP are heterogeneous 
transitional intermediates between LT-HSC and oligopotent progenitors [136]. 
Despite the lack of consensus agreement in differentiating ST-HSC and MPP, 
various groups have used different yet proper gating strategies for functional 
studies for these subsets [132,137]. There are two gating criteria for LT-HSC and 
ST-HSC identification: the first one, is LT-HSC that are designated as Lin-Sca-
24 
 
1+c-Kit+CD34-Flt3- and ST-HSC as Lin-Sca-1+c-Kit+CD34+Flt3+ [13,132]; the 
second one, using the SLAM markers, is LT-HSC that are Lin-Sca-1+c-Kit+ 
CD150+CD48-, MPP1 are Lin-Sca-1+c-Kit+ CD150+CD48+ and MPP2 are Lin-Sca-
1+c-Kit+ CD150-CD48+ [138,139].  
The differentiation pathways in adult murine hematopoiesis 
  Since the LSK cells are enriched with HSC and MPP, the identification of 
lineage-specific progenitors were sought outside of the LSK fraction. The 
common lymphocyte progenitors (CLP) were the first lineage-committed 
progenitors isolated [140]. They were found to be the earliest population to 
express IL-7Rα, the receptor for IL-7, an essential cytokine for T cell and B cell 
development [141]. Therefore, the BM fraction isolated as IL-7Rα+Lin-Sca-1Lowc-
KitLow CLP possess T, B, and NK cell potential but failed to undergo myeloid 
differentiation. The IL-7Rα-Lin-Sca-1+c-Kit+ fraction (commonly known as the LK 
cells) are mainly myeloid progenitor cells [136]. Common myeloid progenitors 
(CMP), megakaryocyte-erythrocyte progenitors (MEP), and granulocyte-
macrophage progenitors (GMP) all reside within the LK population and can be 
fractionated based on the expression level of FcRγII and FcRγIII (FcγRII/III) and 
CD34. CMP are FcγRII/IIILowCD34+, GMP are FcγRII/IIIHighCD34+ and MEP are 
FcγRII/IIILowCD34- [142] (Table 1.1). The CMP differentiates into GMP and MEP. 
GMP further produce granulocytes and macrophages while MEP differentiate into 
megakaryocytes and erythrocytes. The CMP are able to generate all myeloid 
colonies but GMP and MEP have more restricted lineage potentials. Unlike the 
HSC, these progenitors do not have self-renewal capacity upon in vivo 
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transplantation. Instead, they possess the potential to transiently reconstitute the 
specific lineage as shown by their in vitro studies [143] (Figure 1.2).  
Table 1.1 Hematopoietic subsets and immunophenotypic markers. 
Abbreviation Hematopoietic subsets Immunophenotypic 
markers 
LSK Hematopoietic stem and 
progenitor cells  
Lin-Sca-1+c-Kit+ 
LK Myeloid progenitor cells 
enriched 
Lin-Sca-1-c-Kit+ 
LT-HSC Long-term hematopoietic 
stem cells 
Lin-Sca-1+c-Kit+ 
CD150+CD48- 
MPP1 Multipotent progenitors 1 Lin-Sca-1+c-Kit+ 
CD150+CD48+ 
MPP2 Multipotent progenitors 2 Lin-Sca-1+c-Kit+ 
CD150-CD48+ 
CMP Common myeloid 
progenitors 
Lin- IL-7Rα-Sca-1-c-
Kit+FcγRII/IIILowCD34+ 
GMP Granulocytic monocytic 
progenitors 
Lin- IL-7Rα-Sca-1-c-
Kit+FcγRII/III+CD34+ 
MEP Megakaryocyte erythroid 
progenitors 
Lin- IL-7Rα-Sca-1-c-
Kit+FcγRII/IIIlowCD34- 
CLP Common lymphoid 
progenitors 
IL-7Rα+Lin-Sca-1Lowc-
KitLow 
NE Neutrophils Gr1+Mac1+ 
 
Mϕ Macrophages 
 
F480+Mac1+ 
Ery Erythrocytes 
 
Ter119+ 
T T cells 
 
CD3+ or CD4+ or 
CD8+ 
B B cells 
 
B220+ 
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Figure 1.2 Hierarchy of hematopoiesis in the BM of adult mice. 
Hematopoietic differentiation pathway in adult mice and corresponding 
immunophenotypic markers commonly used to distinguish each hematopoietic 
subsets (LT-HSC, Long-term hematopoietic stem cells; MPP, Multipotent 
progenitors; CLP, Common lymphoid progenitors; CMP, Common myeloid 
progenitors; MEP, Megakaryocyte erythroid progenitors; GMP, Granulocytic 
monocytic progenitors; B, B cells; T, T cells; Ery, Erythrocytes; NE, Neutrophils; 
Mϕ, Macrophages). 
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The hematopoietic stem cell niche 
 A niche is a local tissue microenvironment that directly regulates a defined 
type of stem and progenitor cells [144]. In adult human and mice, the BM is the 
primary site of HSC maintenance [145]. The discovery of the SLAM marker has 
greatly improved the specificity of murine HSC localization in the BM via 
fluorescence microscopy. Most Lin-CD150+CD48-CD41- localize adjacent to 
sinusoid vessels in the endosteum of the trabecular bone [130,146,147]. 
Essential cell types identified in the BM HSC niche include the sinusoidal 
osteoblasts, vascular and perivascular endothelial cells, reticular cells, stromal 
cells and BM adipocytes [148-150]. Increasing knowledge of the roles of these 
cell types on HSC function have been generated using mouse models with tissue 
specific gene deletion. For instance, Jagged-1 ligands expressed in the BM 
endothelial cells trigger the activation of Notch signaling and promote HSC 
maintenance [151]. Depletion of osteoblastic cells impaired HSC niches 
formation and indirectly affected normal hematopoiesis in the BM [152]. Whether 
these cellular components in the HSC niche affect HSC functions directly or via 
indirect mechanism still require more investigation. It is critical take into 
consideration the microenvironment niche when studying HSC and 
hematopoiesis during homeostasis or inflammation.  
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Hematopoietic stem cells response to inflammatory signals 
 Cell cycle analysis on the HSC has demonstrated that higher than 70% of 
these cells remain in a quiescent, dormant state. Moreover, it has been found 
that only the dormant HSC were able to reconstitute the entire hematopoietic 
system upon transplantation. As the quiescent HSC enter cell cycle, they also 
lose their long-term engraftment potential [153]. While HSC remain in dormancy 
during homeostasis, they can proliferate and differentiate upon hematopoietic 
stress or infection. In a hemorrhage model, HSC expanded to restore the 
erythrocytes [154], and severe infection was shown to induce CLP proliferation 
as a compensatory response to T cell apoptosis [155]. Similarly, emergency 
granulopoiesis occurs when the granulocytes are rapidly consumed during 
bacterial infection [156]. It was previously believed that the alteration in HSC 
proliferation and differentiation pattern in the HSC was an indirect response to 
infections, aiming to replenish the mature blood cells. Recent studies, however, 
have proved that this hypothesis overlooked a large portion of the whole picture. 
Though residing in the seemingly isolated BM niche, HSC can in fact respond to 
various inflammatory signals directly. Inflammatory cytokines including IFNα, 
IFNγ, TNF-α and G-CSF affect HSC proliferation, differentiation, mobilization and 
engraftment activity [157-162]. Expansion of the LSK population has been 
reported in polymicrobial, bacterial and endotoxin models of systemic 
inflammation [13,163]. Continuous treatment of IFNα and IFNγ elevated HSC cell 
cycle activity in vivo [157,164]. It has been found that alongside promoting the 
LT-HSC to enter the cell cycle, Type 1 IFNs also have proapoptotoic effects on 
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the activated HSC, which hampered their regenerative potentials [165]. Similarly, 
TNF-α, a major pro-inflammatory cytokine produced during sepsis, also mediate 
important effects on the HSC. On one hand, TNF-α inhibits murine HSC growth 
in vitro and excessive TNF-α signaling is associated with BM failure [161,166-
168]. On the other hand, TNF-α produced by CD8+ cells prevented HSC 
apoptosis in vivo and in vitro [169], and loss of baseline TNF-α signaling impaired 
HSC’s self-renewal capacity [170]. Expression of TLRs has been found on the 
surface of HSC, providing molecular evidence that HSC can sense the 
pathogens and pathogenic materials directly [171]. The TLR4 ligand LPS 
stimulates HSC to enter cell cycle and skew for myeloid differentiation [171] . 
Similar to the impact of IFNs, chronic infection or low dose LPS exposure 
impaired the reconstitution capacity of the HSC [172]. In a mouse model of 
severe endotoxemia, acute and high dose LPS exposure triggered LSK cell 
expansion and myeloid differentiation deficiency, ultimately resulting in 
neutropenia [13]. In summary, the HSC are primary sensor of infection-induced 
inflammation. Cytokines and endotoxin significantly alter the hematopoiesis 
dynamics by affecting the HSC. The physiological response of the hematopoietic 
system to environmental factors is of crucial importance for immune cell 
replenishment or pathogen clearance. It is of great importance to return to a 
homeostasis when the danger signal is no longer present. However, what is often 
the case during sepsis, the cytokine storm and endotoxemia is so severe that the 
hematopoietic system was traumatized and unable to regain homeostasis.   
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INFLAMMATORY REGULATION OF MICRORNA 
microRNAs 
 First identified in Caenorhabditis elegans, microRNAs (miRNA) are 
endogenous non-coding RNA with 19-22 nucleotides (nt) [173]. miRNA genes 
are commonly found to co-localize with other protein-encoding genes and share 
the same promoter regulatory machine with the protein-encoding gene. They can 
also be found as an independent gene in the genome. miRNA genes are 
transcribed by the Polymerase II in the nucleus. The primary transcripts of 
miRNA genes are termed pri-miRNA. Pri-miRNA are processed by a 
microprocessor complex composed by the ribonucleas (RNase) III Drosha 
enzyme and the DiGeorge Syndrome Critical Region 8 (DGCR8) protein. 
Processed pri-miRNA become 70-100 nt pre-miRNA, which are then exported 
into the cytoplasm where they are integrated into the RNA-induced silencing 
complex (RISC). Pre-miRNA manifests a hairpin topology structure and is 
cleaved by the RISC with one strand being the passenger strand that is released 
and degraded, while the other strand, termed the guide strand, remains in the 
RISC and guide the complex to the 3’ untranslated regions (3’-UTR) of target 
messenger RNAs (mRNA) for target repression [174-176]. miRNA are key 
components of the gene regulatory network in all multicellular organisms. 
Phylogenetic studies showed high conservation of primary sequences of miRNA 
during evolution [177]. The transcriptional regulation of miRNA provide an 
additional regulation layer for complex biological processes. 
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Sepsis and microRNAs 
 Altered miRNA have been implicated in various disease conditions such 
as cancer, cardiovascular diseases and inflammatory diseases [178]. 
Identification of differential expression of miRNA in the blood of septic patients 
suggested their involvement in sepsis pathogenesis [179]. For instance, 
decreased levels of plasma miR-150 in critically ill patients correlated with 
chances of organ dysfunction and mortality [180]. miR-146a and miR-233 were 
found to be decreased in sepsis patients when compared to healthy individuals 
[181]. Upregulation of miR-133 was found to be correlated with the severity of 
sepsis [182]. Extracellular miRNA are potential diagnostic and prognostic 
biomarkers for sepsis and intracellular miRNA targeting the inflammatory 
signaling pathway are also putative regulators of the disease. Consistent with its 
correlation with disease severity in the serum, miR-146 negatively modulates the 
TLR4 pathway by targeting TLR4 itself and the downstream adapter proteins 
MyD88, IRAK1 and TRAF6 [183,184]. miR-155 is another well-known 
inflammatory miRNA because it is upregulated in a NF-κB dependent manner in 
macrophages and stromal cells during inflammation. Endotoxin treatment greatly 
increased miR-155 expression in liver tissues [185]. A recent study by our group 
revealed that miR-155 is significantly elevated in a chronic inflammatory 
microenvironment induced by loss of Notch signaling, which ultimately 
contributes to myelodysplasia syndrome [139]. Interestingly, the pro-inflammatory 
cytokine TNF-α was identified to be a target of miR-125b in silico [186], and 
decreased transcriptional activity of TNF-α induced by miR-125b has been 
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demonstrated in vitro [185]. The role of miR-21 during inflammation has been 
shown to be cell-type specific. Increased levels of miR-21 have been reported in 
the muscle tissue of sepsis patients [187]. Similarly, miR-21 promotes the 
production of pro-inflammatory mediators in non-hematopoietic cells, and LPS, 
IL-6 and TNF-α can induce miR-21 expression [188-190]. Also, miR-21 has been 
found to target PCDC4, a pro-inflammatory protein, and therefore it has been 
regarded also as a negative regulator to tune down the activated NF-κB signaling 
pathway [191]. Currently, miR-21 is regarded as a switch that could either 
promote or inhibit the inflammatory response depending on whether is an early or 
late phase [192].  
The discovery that many miRNA are altered during sepsis provides 
potential prognostic and diagnostic approaches to better classify septic patients, 
and potentially lead to more personalized treatment. Moreover, intracellular 
miRNA regulating the inflammatory pathways could have therapeutic potentials 
for the treatment of sepsis.     
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SUMMARY AND SIGNIFICANCE 
  Sepsis arises when an individual’s immune system respond to infection in 
an uncontrolled manner. It is a global healthcare problem with high risk of death. 
In industrialized countries like the US, sepsis accounts for more deaths than 
breast cancer, prostate cancer and AIDS combined [193]. With an increased 
number of elderly patients, immune-compromised patients and the emergence of 
antibiotics-resistance superbug, the incidence of sepsis in the future is likely to 
remain the same, or even increased. In developing countries, the situation is 
worrisome due to poor hygiene conditions and the lack of advanced medical 
armamentarium. The rate of hospitalized neonatal infection in developing 
countries have been reported to be 3 to 20-fold higher than in developed 
countries, and did not include the large portion of newborns that are delivered at 
home, which is common in the developing world [194]. Sepsis has imposed and 
continues to impose an enormous economic burden on the global health care 
system. Tremendous amounts of money and efforts have been spent to improve 
the life of patients with sepsis, yet the incidence and rate of mortality in patients 
with sepsis remain high. Most current therapeutic interventions are focused on 
reversing the complications that come along with sepsis instead of targeting the 
fundamental pathological changes in the affected individuals. Despite multiple 
trials put forward to identify the panacea for sepsis in the past, none was able to 
remain on the market due to low efficiency or severe side effects. The highly 
complicated pathology of sepsis and the highly diverse clinical contexts in each 
patient make the journey to conquer the disease very rough. For a long period of 
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time, sepsis studies have been focusing on reversing cytokine storm, coagulation 
dysfunction, and lung/cardiovascular injury. The BM, as an organ which is also 
greatly affected by inflammation, was largely neglected. In fact, BM failure and 
hematopoietic defects have been found in animal and human induced by shock 
and injury [195]. Altered hematopoiesis is a common event occurs upon infection. 
Adequate supply of immune cells requires normal function of the BM. Therefore, 
identifying the BM alteration upon sepsis or septic-like stimulation will broaden 
the scope of therapeutic development.  
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HYPOTHESIS 
 Numerous studies have revealed that hematopoietic cells including HSC 
can directly respond to infection by expressing TLR4, the receptor for Gram-
negative bacteria’s LPS. Previous work in our lab showed TLR4 is indispensable 
for the BM response induced by P. aeruginosa’s LPS, where immunophenotypic 
hematopoietic stem and progenitor cells (HSPC) were found to expand but with 
jeopardized stem cell function and myeloid differentiation was blocked. TLR4 
signaling can be mediated by either the MyD88-dependent pathway or the TRIF-
dependent pathway. In this project, my hypothesis is that both MyD88 and TRIF 
are crucial during the BM response to bacterial infections and I sought to 
determine their distinct contributions to HSC regulation during sepsis (Figure 1.3). 
The specific aims of my project are listed as the following: 
1.  To determine whether BM myeloid suppression induced by P. 
aeruginosa’s LPS is mediated by the TLR4/MyD88 pathway or the 
TLR4/TRIF pathway. 
2. To determine whether the P. aeruginosa’s LPS-induced HSPC injury 
requires the TLR4/MyD88 pathway or the TLR4/TRIF pathway. 
3. To examine putative mediators downstream of the TLR4/MyD88 or 
TLR4/TRIF pathway in contributing to the BM dysfunction during P. 
Aeruginosa’s LPS challenge. 
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Identification of the molecular pathway underlying BM myeloid suppression 
and HSC injury will provide novel therapeutic strategies for preventing 
neutropenia and protecting HSC injury during sepsis.  
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Figure 1.3 Working model 
This diagram shows that the general hypothesis is that both TLR4/MyD88 and 
TLR4/TRIF is important for the BM responses during sepsis. The aim is to 
elucidate the distinct contribution of TLR4/MyD88-dependent and TLR4/MyD88-
independent (TIRF) pathway to hematopoietic responses in the BM during sepsis 
(LT-HSC, Long-term hematopoietic stem cells; MPP, Multipotent progenitors; 
CLP, Common lymphoid progenitors; CMP, Common myeloid progenitors; MEP, 
Megakaryocyte erythroid progenitors; GMP, Granulocytic monocytic progenitors; 
B, B cells; T, T cells; Ery, Erythrocytes; NE, Neutrophils; Mϕ, Macrophages). 
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CHAPTER TWO 
MATERIALS AND METHODS 
 MATERIALS 
1. Mice 
All mice studied were approved by the Institutional Animal Care and Use 
Committee of the Indiana University School of Medicine study protocol # 10252 
and 10275 (Principle Investigator: Nadia Carlesso). Gender-matched mice of 
both sexes between the ages of 8 and 12 weeks were used. 
a. C57BL/6 mice 
C57BL/6 mice were purchased from The Jackson Laboratory and the In Vivo 
Therapeutics Core at Indiana University School of Medicine.  
b. MyD88-/- (MyD88KO and B6.129P2(SJL)-Myd88tm1.1Defr/J) mice 
The MyD88 KO mice originally generated by the Akira Lab (Hyogo, Japan) were 
a generous gift from Dr. Mark Kaplan (Indiana University School of Medicine). 
The B6.129P2(SJL)-Myd88tm1.1Defr/J mice were purchased from The Jackson 
Laboratory. Both strains have eliminated MyD88 function. 
c. TRIF-/- (C57BL/6J-Ticam1Lps2/J) mice 
The TRIF-/- were purchased from The Jackson Laboratory. 
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d. FVB/N-TgN Lys-EGFP reporter mice 
The Lys-EGFP reporter mice were obtained from Dr. Graf from the Center for 
Genomic Regulation, Barcelona, Spain. 
e. BoyJ (B6.SJL-PtrcaPep3b/BoyJ) mice 
The BoyJ mice were purchased from the In Vivo Therapeutics Core at Indiana 
University School of Medicine.  
f. miR-21flox/flox mice 
The miR-21flox/flox mice were a generous gift from Dr. Mircea Ivan for collaborative 
projects. They were crossed with the Mx1-Cre mice. 
g. Mx1-Cre mice  
The Mx1-Cre mice were a generous gift from Dr. Reuben Kapur. 
2. Primers 
Standard polymerase chain reaction (PCR) reactions for genotyping (Table 2.1) 
and quantitative reverse transcription-PCR (qRT-PCR) for gene expressions 
were performed using oligonucleotides synthesized by Invitrogen (Table 2.2). 
qRT-PCR for miRNA expression (Table 2.3) were performed using 
commercialized primers from TaqMan®  (Applied Biosystems). 
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Table 2.1 Genotyping Primers 
Gene Forward (5’-3’) Reverse (5’-3’) Mutant (5’-3’) 
MyD88  TGGCATGCCTC
C 
ATCATAGTTAAC
C 
GTCAGAAACAA
C 
CACCACCATGC 
ATCGCCTTCTA
TCGCCTT 
CTTGACG 
miR21 flox ACAGCTTTCTTT
CCTAGAATTGG
C 
GTCTCACAAGA
CATAAGGACCA
CAA 
 
Cre CATTTGGGCCA
GCTAAACAT 
ATTCTCCCACC
GTCAGTACG 
 
 
Table 2.2 Quantitative RT-PCR Primers 
Gene Forward (5’-3’) Reverse (5’-3’) 
PU.1 AGAAGCTGATGGCTTGGAGC GCGAATCTTTTTCTTGCTGCC 
CEBP/α AAAGCCAAGAAGTCGGTGGAC CTTTATCTCGGCTCTTGCGC 
TLR4 TCTGAGCTTCAACCCCTTGA TGCCATGCCTTGTCTTCAATT 
MYD88 TAGTCGCAGACAGTGATGAAC CTGCAGAGCAAGGAATGTGA 
TRIF CAGCTCAAGACCCCTACAGC CTCCCACACAGCCTCGTC 
GAPDH AAGCCCATCACCATCTTCCA TAGACTCCACGACATACTCA 
 
Table 2.3 miRNA RT-PCR Primers 
Gene Company Catalog Number 
hsa-miR-21 Applied Biosystems 4331182 
U6 snRNA Applied Biosystems 4427975 
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3. Antibodies 
Table 2.4 Antibodies for Flow Cytometry 
Primary Antibody Company Clone 
CD3-FITC BD Biosciences 145-2C11 
CD4-FITC BD Biosciences RM4-5 
CD8-FITC BD Biosciences 53-6.7 
B220-FITC BD Biosciences RA3-6B2 
Gr-1-FITC BD Biosciences RB6-8C5 
Mac1-FITC BD Biosciences M1/70 
Ter119-FITC BD Biosciences TER-119 
CD45.2-FITC BD Biosciences 104 
CD3-PE BD Biosciences 145-2C11 
CD4-PE BD Biosciences H129.19 
CD8-PE BD Biosciences 53-6.7 
B220-PE BD Biosciences RA3-6B2 
Gr-1-PE BD Biosciences RB6-8C5 
Mac1-PE BD Biosciences M1/70 
Ter119-PE BD Biosciences TER-119 
CD45.2-PE BD Biosciences 104 
Flt3-PE BD Biosciences A2F10.1 
Sca1-PE BD Biosciences D7 
CD48-PE eBioscience HM48-1 
CD150-PE Biolegend TC15-12F12.2 
CD48-APC eBioscience HM48-1 
CD150-APC eBioscience 9D1 
cKit-APC BD Biosciences 2B8 
CD11b-APC BD Biosciences M1/70 
CD16/CD32-APC eBioscience 93 
Sca1-PE-Cy5.5 Invitrogen SCA1 
CD45.2-PE-Cy5.5 eBioscience 104 
B220-PE-Cy5.5 eBioscience RA3-6B2 
IL7-R-PE-Cy7 eBioscience A7R34 
Sca-1-PE-Cy7 eBioscience D7 
cKit-APC-Cy7 eBioscience 2B8 
CD11b-APC-Cy7 Biolegend M1/70 
CD34-Pacific Blue eBioscience RAM34 
CD48-Pacific Blue eBioscience HM48-1 
Annexin V- PE BD Biosciences  
Annexin V-APC BD Biosciences  
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4. Commercial Kits 
Table 2.5 Commercial Kits 
Kit Company Catalog Number 
APC BrdU Flow Kit BD Pharmingen 557892 
Lin- Cell Depletion 
Kit, mouse 
Miltenyi Biotec 130-090-858  
Fast Universal PCR 
Master Mix (2X) 
TaqMan® 4352042 
MicroRNA Reverse 
Transcription Kit 
TaqMan® 4366596 
RNAqueous®-Micro 
Total RNA Isolation 
Kit 
Life Technologies AM1931 
Brilliant III Ultra-Fast 
SYBR® Green 
QRT-PCR Master Mix 
Agilent Technologies, 
Inc. 
600882 
iScript™ cDNA 
Synthesis Kit 
Bio-Rad 1708891 
GoTaq® DNA 
Polymerase 
Promega M3005 
Mouse G-CSF 
Quantikine ELISA Kit 
R & D Systems MCS00 
Mouse TNF-alpha 
Quantikine ELISA Kit 
R & D Systems MTA00B 
Mouse IFN-alpha 
ELISA Kit 
R & D Systems 42120-1 
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5. Reagents 
Table 2.6 Reagents 
Reagent Company Catalog number 
Lipopolysaccharides 
from Pseudomonas 
aeruginosa 10 
Sigma Aldrich L8643 
IL-3, mouse R & D systems 403-ML-010 
SCF, mouse R & D systems 455-MC-010 
TRITC dextran 150 
100mg 
TdB Consultancy TD150-100mg 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
METHODS 
1. Endotoxemia model 
Mice were subjected with i.p. inoculation of 2mg/kg (approximately 20-
50μg/mouse) of P. aeruginosa LPS (Sigma) and euthanized 24 hours after LPS 
challenge for BM analyses. Inoculation with this dose of LPS was able to 
recapitulate the BM responses induced by inoculation with the P. aeruginosa [13]. 
Endotoxemia model was used as the major mouse sepsis model in the current 
project to simplify the experimental procedure.  
2. Polymicrobial sepsis induction 
Sepsis was induced by cecal ligation and puncture (CLP) [196]. Briefly, mice 
were anesthetized with ketamine:xylazine (100 mg/kg:10 mg/kg, i.p.), and severe 
sepsis was induced by perforating their cecum with one superficial puncture 
using an 21G1 needle. Sham mice received cecal ligation but no perforation of 
the cecum. Mice were euthanized 24 hours after the CLP surgery for BM 
analyses.  
3. Generation of chimeras  
To develop chimeras with MyD88-/- microenvironment and WT hematopoietic 
cells (MyD88-/- ME), total BM cells (1 to 2 x 106) from donor C57BL/6-CD45.1 
(Boy/J)  mice were transplanted via tail-vein injection into lethally irradiated ( a 
split dose of 12Gy) MyD88-/- (CD45.2) recipients. To develop chimeras with 
MyD88-/- hematopoietic cells and WT microenvironment (MyD88-/- donor), total 
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BM cells (1 to 2 x 106) from donor MyD88-/- (CD45.2) mice were transplanted via 
tail-vein injection into lethally irradiated (a split dose of 12Gy) Boy/J recipients. 
4. Reconstitution competitive assay 
Boy/J recipients were lethally irradiated with a split dose of 12Gy 8 hours before 
transplantation. LSK donor cells were derived from PBS or LPS challenged WT, 
MyD88-/- or TRIF-/- mice. Competitive BM cells were prepared as a single-cell 
suspension from Boy/J CD45.1+ mice and admix with the CD45.2+ LSK donor 
cells. A total of 2500-5000 LSK control or septic LSK cells were transplanted into 
recipients together with 105 competitive CD45.1+ cells. Engraftment was 
evaluated at 4-week intervals until week 24 by collecting the peripheral blood for 
analysis of CD45.2 and lineage markers. At week 24, all recipients were 
sacrificed for BM analysis.  
5. Homing assay 
LSK cells were sorted from PBS- or LPS- challenged C57BL/6-CD45.2 mice. 
LSK cells (2.5 to 5 x 104) were transplanted into lethally irradiated Boy/J-CD45.1 
mice. Recipient mice were sacrificed 16 hours post-transplantation, and BM cells 
were recovered and analyzed for CD45.2 distribution in the BM by FACS. 
6. Flow cytometry analysis 
BM and peripheral blood cell suspensions were labeled with monoclonal 
antibodies to define distinct hematopoietic subsets (Table 2.7). Cells were 
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acquired on an LSR II (BD Biosciences). Events (0.5 to 5 x 106 per staining) were 
analyzed with FlowJo 7.6.5 and FlowJo 7.2.5.  
Table 2.7 Identification of distinct hematopoietic subsets 
Hematopoietic Subsets Surface Marker 
Long-term hematopoietic stem 
cells (LT-HSC) 
Lin-Sca1+c-Kit+CD150+CD48- 
Multipotent progenitors 1 (MPP1) Lin-Sca1+c-Kit+CD150+CD48+ 
Multipotent progenitors 2 (MPP2) Lin-Sca1+c-Kit+CD150-CD48+ 
LSK Lin-Sca1+c-Kit+ 
Common myeloid progenitors 
(CMP) 
Lin-IL-7Rα-Sca1-c-
Kit+CD34+FcγRII/IIIlo 
Granulocytic monocytic 
progenitors (GMP) 
Lin-IL-7Rα-Sca1-c-
Kit+CD34+FcγRII/IIIhi 
Megakaryocyte erythroid 
progenitors (MEP) 
Lin-IL-7Rα-Sca1-c-Kit+CD34-
FcγRII/IIIlo 
Common lymphoid progenitors 
(CLP) 
Lin-IL-7Rα+Sca1loc-Kitlo 
Granulocytes and monocytes Gr1+Mac1+ 
B cells B220+ 
T cells CD4+/CD8+/CD3+ 
 
7. Cell sorting 
For hematopoietic stem and progenitor cell sorting, BM cells were incubated with 
Biotin-antibody cocktail (Miltenyi Biotec) followed by incubation with Anti-biotin 
microbeads (Miltenyi Biotec) and negative selection by magnetic-activated cell 
sorter (MACS) separation system. Lineage-depleted BM cells were labeled with 
anti-c-Kit, anti-Sca1, anti-IL-7R, anti-Fcγ, anti-CD34 and sorted. For mature 
hematopoietic cell sorting, BM cells were stained with anti-Gr1, anti-Mac1. All the 
cells were sorted with the FacsAria (BD Biosciences). 
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8. Cell cycle and apoptosis analysis 
PBS or LPS challenged mice were injected with bromodeoxyuridine (BrdU) (1-
2mg/mouse) 18 hours prior to sacrifice (6 hours after LPS or PBS injection). Total 
BM cells were harvested 24hours from LPS (or PBS) challenge. BM cell cycle 
characterization was performed using the BrdU-APC Flow Kit (BD Pharmingen) 
in combination with markers for LSK and Gr1+Mac1+ cells. Cell death was 
measured by labeling BM cells with Annexin V and Propidium iodide (PI) in 
combination with markers for LSK, Gr1 and Mac1. Samples were analyzed by 
FACS. 
9. In vitro differentiation assay 
BM cells from PBS or LPS-challenged WT, MyD88-/- and TRIF-/- mice were 
harvested from femurs by crushing with phosphate-buffered saline (PBS)/0.2mM 
EDTA. Cells were lineage depleted using the lineage cell depletion kit (Miltenyi 
Biotec) and sorted for CMP and GMP. Cells were cultured in IMDM + 10%FBS 
supplemented with SCF (50 ng/mL) and IL-3 (20 ng/mL), seeded at 1 x 104 
cells/mL in 96-well plates and cultured at 37 °C, 5% CO2 for up to 6 days. Cells 
were collected at day 2 and day 4 and stained with Gr1 and Mac1 to determine 
the myeloid differentiation potential of sorted cells.   
10. qRT-PCR and miRNA quantification 
RNA from sorted BM cells was purified with the RNAqueous micro kit (Ambion). 
qRT-PCR was performed with SYBR green II Brilliant (Strategene) and the 
primers shown in Table 2.2 (Invitrogen).  miRNA expression was assessed by 
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qRT-PCR (Applied Biosystems) with miRNA-specific TaqMan® miRNA Assays 
(has-miR-21, U6snRNA) on an ABI 7900HT FAST platform (Applied Biosystem). 
11. Imaging acquisition and image analysis 
Two-photon images of calvarium BM were collected using Olympus XLUMPLFL 
20xW, NA 0.95 objective. Z-stacks were collected through the depth of tissue (60 
μm Z-stacks) from 6 regions of calvarium BM, at step size settings of 1μm and 
512x512 pixels frame size. Projection images were created using MetaMorph 
imaging software (Molecular 135 Devices). Volume rendering software Voxx was 
used to create 3D reconstructions of BM. 
12. Statistical analysis 
Results were evaluated by performing unpaired t-tests or ANOVA using 
GraphPad Prism Version 6.0 software (GraphPad Software) and Excel 2010. 
Data were expressed as mean ± SEM unless indicated otherwise. *p < 0.05 was 
determined significant, and **p < 0.01 were considered highly significant. 
 
 
 
 
 
 
49 
 
CHAPTER THREE 
ROLE OF MYD88 AND TRIF IN MEDIATING BM RESPONSE DURING 
PSEUDOMONAS AERUGINOSA’S LPS CHALLENGE 
INTRODUCTION 
In the BM, the myelosuppression and neutropenia induced by P. 
aeruginosa inoculation are recapitulated by the injection of P. aeruginosa’s LPS 
(20-50μg/mouse). These responses are largely due to a differentiation block in 
the HSPC. Mice with functionally depleted TLR4 are resistant to LPS-induced 
myeloid suppression [13].  
TLR4 is one of the extracellular receptors for LPS sensing. TLR4 
activation can be mediated by MyD88 and/or by TRIF. The MyD88-dependent 
pathway induces early activation of NF-κB and Activation Protein 1 (AP-1), 
resulting in production of inflammatory cytokines. The TRIF pathway, also known 
as the delayed-MyD88-independent pathway, leads to the activation of IRF3 and 
late NF-κB activation, which induces the production of IFN-β [197].  
Here, I evaluated the distinct contribution of TRIF and MyD88 to the BM 
response during LPS-induced endotoxemia (Figure 1.3). The ultimate objective is 
to identify the cellular and molecular mechanisms underlying such alterations to 
develop new therapeutic approaches for the treatment of sepsis. 
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RESULTS 
3.1 P. aeruginosa’s LPS induced LSK expansion in the BM is TLR4/TRIF 
dependent 
It has been previously reported that P. aeruginosa’s LPS induced an 
expansion of LSK cells in a TLR4-dependent manner. LSK cell is a cell subset 
enriched with HSPC [13]. To identify whether TLR4-mediated HSPC expansion 
upon LPS stimulation is dependent on MyD88 or TRIF, we challenged WT, 
MyD88-/- and TRIF-/- mice with LPS for 24 hours and performed 
immunophenotypic analysis of the BM cells. As expected, WT mice responded to 
LPS challenge with a significant increase in the percentage of LSK cells. LPS 
also induced a dramatic expansion of LSK cells in the MyD88-/- mice. 
Interestingly, we observed a significantly smaller increase (2-fold increase) in 
LSK cells in the TRIF-/- mice compared to WT and MyD88-/- mice (Figure 3.1 A, 
C). To further identify the subsets within the HSPC that were affected by LPS 
stimulation, we used SLAM markers to distinguish LT-HSC (Lin-Sca-1+c-
Kit+CD150+CD45-), MPP1 (Lin-Sca-1+c-Kit+CD150+CD45+) and MPP2 (Lin-Sca-
1+c-Kit+CD150-CD48+) (Figure 1.2 and Figure 3.1 B). LPS leads to a significant 
increase in the percentage of LT-HSC in WT and MyD88-/- mice but no change 
was seen in the TRIF-/- mice (Figure 3.1 D). Similar to the results from a Type-I 
IFN study [165], I did not find alteration in the absolute number of LT-HSC upon 
LPS challenge in WT mice (Figure 3.1 D), despite an increased frequency 
observed in both WT and MyD88-/-. Significant expansion of MPP1 and MPP2 in 
LPS-challenged WT and MyD88-/- mice was observed (Figure 3.1 E-F). In 
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contrast, in TRIF-/- mice, absolute number of MPP1 and MPP2 following LPS 
challenge were similar to PBS control (Figure 3.1E-F).  
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Figure 3.1 P.Aeruginosa’s LPS-induced LSK expansion in the BM in a 
TLR4/TRIF dependent manner. 
(A-B) Representative FACS plots for LSK populations (A) or HSPC (B) labeled 
with SLAM family marker (LT-HSC: Lin-Sca-1+c-Kit+CD150+CD48-; MPP1: Lin-
Sca-1+c-Kit+CD150+CD48+; MPP2: Lin-Sca-1+c-Kit+CD150-CD48). (C-F) 
Percentage in the gated Lin- population (left) or absolute cell numbers per femur 
(right) in PBS versus LPS challenged mice of LSK (C), LT-HSC (D), MPP1 (E) 
and MPP2 (F) (n = 5-14). Data represent mean ± SEM. LPS vs. PBS: * p < 0.05, 
** p < 0.01, unpaired t test; LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, 
##p < 0.01, unpaired t test. 
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3.2 The TLR4/TRIF-dependent pathway is required for the LSK expansion in 
polymicrobial sepsis. 
Next, I examined whether the LSK expansion observed during 
endotoxemia was a representative response during polymicrobial sepsis. To this 
end, we used a model of severe peritonitis induced by CLP in WT, MyD88-/- and 
TRIF-/- mice. 4 out of 16 WT mice died within 24 hours after the CLP surgery and 
were unsuitable for BM analysis due to massive cell death in the marrow. 
Analysis of the HSPC fraction in CLP and Sham control WT mice revealed a BM 
response similar to the mice that were challenged with LPS. Absolute number of 
both LSK and MPP1 fraction increased significantly upon CLP in WT mice, and 
this response required both MyD88 and TRIF (Figure 3.2). No significant 
alteration in the LT-HSC absolute numbers was observed except for a mild 
incline trend in the MyD88-/- mice. Surprisingly, I also found that there was a four-
fold increase in the MPP1 absolute numbers in the TRIF-/- mice (Figure 3.2). The 
discrepancy observed in the CLP model could be contributed to the activation of 
other inflammatory pathways such as the TLR2 and TLR9 [198,199]. Despite this 
divergence, I confirmed that expansion of HSPC were also present in the CLP 
polymicrobial sepsis model, which better recapitulate the actual clinical scenario.  
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Figure 3.2 BM responses in the HSPC compartment during polymicrobial sepsis. 
(A-D) Absolute numbers of cells per femur in CLP-challenged versus Sham-
treated mice in BM LSK (A), LT-HSC (B), MPP1 (C) and MPP2 (D) (WT: n = 6-
11; MyD88-/- and TRIF-/-: n = 3-5). Data represent mean ± SEM. LPS vs. PBS: *p 
< 0.05, **p < 0.01, unpaired t test; LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 
0.05, ##p < 0.01, unpaired t test. 
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3.3 Expansion of LSK is marginally due to upregulation of Sca-1 in the myeloid 
progenitors. 
It is widely known that LPS induces IFN and TNF-α production in mouse 
and human [200-204]. Following LPS and sepsis challenge, the levels of Sca-1 
expression on HSPC were overall increased (Figure 3.3A). Previous research 
found that the expression of the canonical HSPC marker Sca-1 in progenitors 
can be induced by IFNs and TNF-α [205,206]. Therefore, one could argue that 
the LSK expansion observed in the current endotoxin model is due to re-
expression of Sca-1 by Sca-1-negative myeloid progenitor cells. To examine this 
hypothesis, I used the Lys-EGFP reporter mice to track the myeloid compartment 
in control and LPS-mice. In the Lys-EGFP reporter mice, green fluorescent 
protein (GFP) expression is driven by the myeloid-specific lysozyme promoter 
[207]. The GFP+ fraction should reside only in the myeloid lineage cells. If the 
hypothesis stated above were true, I would expect to see increased level of GFP 
in the expanded LSK fraction. The GFP fluorescence intensity were examined in 
the LSK, LT-HSC, MPP, CMP, GMP and Gr1+Mac1+ compartments. The 
percentage of GFP+ cells in the myeloid subsets were comparable with results 
derived by Miyamoto et al. [208]. Consistent with the published results [13], the 
GFP+ fraction in the Gr1+Mac+, GMP and CMP compartments were significantly 
reduced, confirming the myeloid differentiation block (Figure 3.3 B). Interestingly, 
higher expression of GFP was observed in the LSK, LT-HSC and MPP from LPS 
treated mice (Figure 3.3 B), indicating that the expanded LSK cells were indeed 
“contaminated” with some myeloid progenitors that re-express Sca-1. 
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Comparison of the absolute number of the total HSPC with those that are GFP+, 
however, demonstrated that the contaminating myeloid progenitor cells only 
make up a very small fraction of the expanded HSPC during LPS challenge 
(Figure 3.3 C).  
 In summary, this result showed that although Sca-1 re-expression in 
myeloid progenitors occurs during LPS challenge in vivo, it is not the key cellular 
mechanism underlying the HSPC expansion. In other words, a large fraction of 
the expanded LSK cells are not derived from myeloid progenitors that re-express 
Sca-1, but rather primitive LSK cells.  
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Figure 3.3 GFP expressions in different cellular subsets in the BM during LPS 
challenge.  
(A) Histogram shows the intensity of Sca-1 in LSK cells from cells from the BM of 
LPS or PBS challenged WT, MyD88-/- and TRIF-/- mice (n = 4-5). (B) 
Representative FACS plots show GFP expression on granulocytes, CLP, GMP, 
LSK, LT-HSC and MPP (n = 3-4). (C-E) Absolute number per femur of total LSK, 
LT-HSC and MPP (Red) and GFP+ LSK, GFP+ LT-HSC and GFP+ MPP (Green) 
(n = 3-4). Data represent mean ± SEM. *p < 0.05, **p < 0.01, unpaired t test. 
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3.4 P. aeruginosa’s LPS induced cell cycle activation in LSK cells in a TRIF and 
MyD88 dependent manner.  
In order to study the cellular mechanism underlying the expansion of LSK 
cells in response to LPS exposure, I used in vivo BrdU incorporation assay to 
analyze the cell cycle activity of LSK cells from WT, TRIF-/- and MyD88-/- mice 
challenged with either LPS or PBS (control). BrdU was injected into the mice 6 
hours after LPS challenge (18 hours prior to sacrifice). In vivo cell cycle analysis 
showed that LSK cells in the WT mice challenged with LPS had a significantly 
increased cycling activity and reduced quiescence compared to PBS controls 
(Figure 3.4 A). In accordance with the LSK pattern in TRIF-/- mice, there were no 
alterations in cell cycle activity in the LSK cells from LPS TRIF-/-. Surprisingly, 
however, unlike LPS WT mice, we did not observe any increase of cell cycle in 
MyD88-/- LSK cells and the percentage of quiescent cells remained unchanged in 
the expanded LSK cells. The cell cycle analyses suggested that the expanded 
septic LSK cells from WT and MyD88-/- mice maintain different cellular 
characteristics (Figure 3.4 A).  
In order to determine whether LPS exposure induce apoptosis in the 
primitive HSPC population, LSK cells from normal and septic mice from all three 
genotypes were studied for cell death using both Annexin/PI and Sub-G1. Both 
criteria showed that a very low percentage of LSK cells undergo apoptosis or 
necrosis, and there were no significant differences between normal and septic 
LSK cells in all three genotypes (Figure 3.4 B).  
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Collectively, these data showed that LPS-induced expansion of HSPC, 
especially LT-HSC, was dependent on the TLR4/TRIF pathway but not the 
MyD88 pathway. The expansion of the LSK cell pool from WT septic mice was 
largely due to cell cycle activation. However, quiescence is preserved in 
expanded MyD88-/- septic LSK cells, suggesting that mechanisms other than the 
cell cycle activation, such as delayed HSC differentiation resulting in slower 
egression from the primitive to the differentiated pool, may participate to this 
process following LPS. 
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Figure 3.4 Acute LPS exposure increase LSK proliferation in a TRIF and MyD88 
dependent manner. 
(A) Left: Representative FACS plots of BrdU/7-AAD incorporation in LSK cells 
from PBS or LPS challenged WT, TRIF-/- and MyD88-/-; Right: Bar graph shows 
mean percentage of BrdU-incoporated S-phase and G0/G1 phase in LSK cells (n 
= 4-9).(B) Left: Bar graph shows the mean percentage of apoptotic cells in LSK 
cells from PBS or LPS challenged WT, TRIF-/- and MyD88-/-; Right: Bar graph 
shows the mean percentage of Sub-G1 subsets in LSK cells (n = 4-5). Data 
represent mean ± SEM. *p < 0.05, **p < 0.01, unpaired t test. 
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3.5 Absence of MyD88 but not TRIF prevents LPS-induced myelosuppression in 
vivo.  
To further address the molecular mechanisms underlying myeloid 
suppression, we characterized the myeloid progenitors and mature myeloid cells 
in WT, TRIF-/- and MyD88-/- mice stimulated with LPS or PBS. Multiparameter 
immunophenotypic analyses showed that LPS caused a reduction of CMP, GMP 
and MEP in the WT and TRIF-/- mice. While the CMP were decreased in LPS-
challenged MyD88-/- mice, the GMP subsets were greatly protected by the loss of 
MyD88 signaling (Figure 3.5 A, C, D). Flow cytometry analyses of the BM 
Gr1+/Mac1+ population, which include monocytes and neutrophils, revealed that 
LPS-induced neutropenia required activation of the MyD88 pathway but not TRIF 
(Figure 3.5 B, E). This effect was not due to increased survival as following LPS 
cell death within the LK was negligible whereas a notable increase was observed 
in the Gr1+/Mac1+ population (15-20%); however, cell death rates were similar in 
all genotypes (Figure 3.5 F). In conclusion, activation of the TLR4/MyD88 
pathway played a dominant role in mediating myeloid suppression in the BM 
upon septic endotoxemia. 
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Figure 3.5 LPS induced myeloid suppression in a MyD88 dependent manner.  
(A-B) Representative dot-plots for myeloid progenitors CMP, GMP (A) and 
Gr1+Mac1+ (B) in the BM of PBS and LPS-treated WT, TRIF-/- and MyD88-/- mice. 
(C-D) Percentage and absolute number/mouse of CMP (C) and GMP (D) (n = 7-
16). (E) Average of the percentage and absolute number/mouse of granulocytes 
(n=7-28). (F) Percentage of apoptotic cells in LK and Gr1+Mac1+ cells (n = 4-5). 
Data represent mean ± SEM. LPS vs. PBS: *p < 0.05, **p < 0.01, unpaired t test; 
LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, ##p < 0.01, unpaired t test.   
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3.6 Absence of MyD88 but not TRIF prevents myelosuppression during 
polymicrobial sepsis. 
 Next, we examined the myeloid differentiation in the BM of CLP 
challenged mice. WT and TRIF-/- mice exhibited loss of CMP, GMP and 
granulocytes 24 hours after CLP challenge. In contrast, MyD88-/- mice stimulated 
with CLP showed normal myeloid differentiation and with normal level of CMP, 
GMP and neutrophils (Figure 3.6). Thus, loss of MyD88 prevents 
myelosuppression also in the settings of polymicrobial sepsis.  
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Figure 3.6 Polymicrobial sepsis induced myeloid suppression in the BM in a 
MyD88 dependent manner.  
Bar graphs indicate the mean of absolute number of BM CMP, GMP and 
Gr1+Mac1+ per femur in CLP challenged versus Sham treated mice (n = 3-10).  
Data represent mean ± SEM. LPS vs. PBS: *p < 0.05, **p < 0.01 unpaired t test; 
LPS-WT vs. LPS-MyD88-/- vs. LPS-TRIF-/-: #p < 0.05, ##p < 0.01, one-way 
ANOVA. 
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3.7 Activation of MyD88 impairs CMP’s ability to differentiate  
 Next, I characterized at what stage of the hematopoietic hierarchy did the 
activation of the MyD88 pathway block myeloid differentiation. Since the HSPC 
phenotype was not affected by the loss of MyD88 as shown in previous results 
(3.1-3.2), I focused on the myeloid progenitors, CMP and GMP. CMP and GMP 
were sorted from WT, MyD88-/- and TRIF-/- mice challenged with LPS or PBS. 
Sorted cells were cultured with IL-3 and SCF for differentiation assay in vitro 
(Figure 3.7 A). At day 4, cells isolated from normal or endotoxemia mice were 
subject for flow cytometry analyses to compare their myeloid differentiation 
capacity. CMP isolated from WT and TRIF-/- mice challenged with LPS 
demonstrated a delayed myeloid differentiation. In contrast, loss of MyD88 
prevented this delay (Figure 3.7 B). Interestingly, GMP (collected at day 2) from 
LPS-challenged mice from WT, MyD88-/- and TRIF-/- manifested no differences in 
their myeloid differentiation dynamics compared to respective PBS control 
(Figure 3.7 C). Collectively, these in vitro data show that activation of the 
TLR4/MyD88 signal in the BM impairs CMP’s ability to differentiate.  
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Figure 3.7 CMP and GMP differentiation assay. 
(A) Experiment design for the differentiation assay for CMP and GMP sorted 
subsets from LPS or PBS challenged WT, MyD88-/- and TRIF-/- mice. (B) 
Representative contour plots for myeloid differentiation from CMP at day 4; bar 
graphs show average of mature myeloid cells differentiated from plated CMP (n = 
3-4). (C) Contour plots for myeloid differentiation from GMP at day 4; bar graphs 
show average of mature myeloid cells differentiated from plated GMP (n = 2-4). 
Data represent mean ± SEM. LPS vs. PBS: *p < 0.05, **p < 0.01; LPS-WT vs. 
LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, ##p < 0.01, unpaired t test. 
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3.8 P. aeruginosa’s LPS induced distinct cytokine production profile in WT, 
MyD88-/- and TRIF-/- mice.  
 In addition to affecting the intrinsic properties of hematopoietic cells, loss 
of MyD88 in the microenvironment can affect hematopoiesis, in particular through 
production of cytokines [209]. G-CSF, TNF-α and IFNα, are critical hematopoietic 
cytokines strongly induced during sepsis and endotoxemia. Measurement of 
these cytokines in the serum showed that MyD88-/- mice were defective in 
inducing all these tree cytokines following LPS, in contrast to WT mice, which 
induced all of them, and TRIF-/- mice, which were defective in induction of TNF-α 
and IFNα (Figure 3.8 B, C) but maintained induction of G-CSF (Figure 3.8 A). 
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Figure 3.8 Cytokine productions in the serum of LPS-challenged WT, MyD88-/- 
and TRIF-/- mice. 
(A) Average concentration of G-CSF in the serum of LPS or PBS challenged WT, 
TRIF-/- and MyD88-/- mice (n = 3-5). (B) Average concentration of TNF-α in the 
serum of LPS or PBS challenged WT, TRIF-/- and MyD88-/- mice (n = 3-5). 
(C)Average concentration if IFNα in the serum of LPS or PBS challenged WT, 
TRIF-/- and MyD88-/- mice (n = 3-5). Data represent mean ± SEM. LPS vs. PBS: 
*p < 0.05, **p < 0.01, unpaired t test. 
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3.9 Both cell-autonomous and non-cell autonomous activation of MyD88 
contributes to myelosuppression and neutropenia induced by LPS. 
Our observations indicate that MyD88 and TRIF contribute in different 
ways to two different ways to the BM response to sepsis. While TRIF leads to 
LSK expansion, MyD88 is required for myeloid differentiation block. Since loss of 
MyD88 could prevent LPS-induced BM neutropenia in our mouse model, we 
hypothesize that manipulation of MyD88 could provide a therapeutic target for 
the prevention of neutropenia in sepsis. To further understand the contribution of 
direct (cell-autonomous) and indirect (non cell-autonomous) MyD88 activation to 
myeloid suppression, we generated chimeric mice.  Reciprocal transplantations 
were performed to generate BM chimeric mice with MyD88 KO (CD45.2+) 
hematopoiesis in a WT (CD45.1+) microenvironment background (MyD88-/- 
Donor) and WT (CD45.1+) hematopoiesis in a MyD88 KO (CD45.2+) 
microenvironment background (MyD88-/- ME) (Figure 3.8 A). As expected, 
neither MyD88-/- Donor nor MyD88-/- ME were able to revert the LSK expansion 
after LPS challenge (Figure 3.9 B). However, a reduced CMP, GMP and MEP 
populations were seen in both chimeras (Figure 3.9 C-E). Comparative analysis 
of the mature myeloid cells revealed that although LPS challenge lead to a 
significant decrease in mature myeloid cells (Gr1+/Mac1+) in both chimeras, the 
Gr1+/Mac1+ population in the LPS-MyD88-/- Donor and MyD88-/- ME was 
significantly (p < 0.01) higher than in the LPS-WT. Moreover, we noticed that the 
combination of myeloid protective effects by both chimeras was similar to the 
parental MyD88-/- mice (Figure 3.9 F). The Gr1+/Mac1+ population among WT, 
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MyD88-/- and both chimeras under normal (PBS) conditions were compared and 
no significant differences were found, thus excluding the artifact that the partial 
rescue arose from myeloid expansion in the chimeras due to irradiation (Figure 
3.9 F). Collectively, I found that both cell-autonomous and non-cell autonomous 
activation of MyD88 contributes to myelosuppression and neutropenia. 
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Figure 3.9 Contribution of cell-autonomous and non-cell autonomous effect of 
MyD88 activation to myeloid suppression in the BM during LPS exposure.  
(A) Generation of MyD88-/- Donor and MyD88-/- ME chimeras through reciprocal 
transplantation. (B) Mean percentage of LSK cells in donor-derived Lin- 
population from WT, MyD88-/-, MyD88-/- Donor and MyD88-/- ME chimeras.(C-E) 
Mean percentage of CMP, GMP and MEP cells in donor-derived Lin- population 
from WT, MyD88-/-, MyD88-/- Donor and MyD88-/- ME chimeras. (F) Mean 
percentage of donor-derived mature myeloid cells from WT, MyD88-/-, MyD88-/- 
Donor and MyD88-/- ME chimeras (n = 7-14). Data represent mean ± SEM. LPS 
vs. PBS: *p < 0.05, **p < 0.01; LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 
0.05, ##p < 0.01; LPS-WT vs. LPS-chimeras: $$p < 0.01, two-way ANOVA.  
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3.10 P. aeruginosa’s LPS increased BM vascular permeability in a MyD88 
dependent manner. 
Results from the reciprocal transplantation showed that MyD88 ablation in 
the BM microenvironment could partially preserve mature myeloid cells, 
suggesting that activation of the TLR4/MyD88 pathway in the BM niche cells 
might also contribute to myeloid differentiation block. Indeed, a recent study 
reports the importance of endothelial TLR4 in replenishing emergency 
granulopoiesis during mild infection [210]. To better understand the potential role 
of MyD88 in the BM microenvironment, we used intravital microscopy. Our group 
has optimized intravital multiphoton fluorescence microscopy (IVFM) of the BM 
from mouse calvarium, and this technique has allowed us to study the change in 
the microenvironment, in particular the function of the BM vascular niche. 
Following LPS, the vasculature changed its properties: vessels are more dilated 
and there is increased permeability. We could observe these effects on WT and 
TRIF-/- mice. Interestingly, I found that loss of MyD88 preserved the integrity of 
the BM vasculature and the vessels were less dilated after 24 hours of LPS 
challenge (Figure 3.10 A). I further performed permeability analysis on WT and 
MyD88-/- vasculature by measuring the intensity ratio of the dextran in the 
intersected tissue and the dextran inside the vessels. Indeed, I found a significant 
increase of vasculature permeability in LPS-WT mice while there was an 
unaltered vasculature intensity ratio in LPS-MyD88-/- mice (Figure 3.10 B). 
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Figure 3.10 Loss of MyD88 prevents calvarium BM vascular injury during LPS 
challenge.  
(A) IVFM imaging of calvarium BM vasculature in Wild-type, MyD88-/- and TRIF-/- 
animal challenged with LPS or PBS as control. Vasculature was defined by 
injection of Dextran-Texas Red. (B) Calvarium bone BM vasculature permeability 
measured by the average intensity ration in WT and MyD88-/- mice (n = 4-5). 
Data represent mean ± SEM. LPS vs. PBS: *p < 0.05, **p < 0.01, unpaired t test. 
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CONCLUSION AND DISCUSSION 
Myelosuppression has been reported in burn P. aeruginosa models as 
well as in LPS endotoxin models [13,211]. Such alteration was also present in 
the severe CLP polymicrobial sepsis model, demonstrating that the BM response 
I characterized here can be extended to different bacterial models of sepsis. It is 
important to note that various studies have reported the expansion of myeloid 
progenitor and mature cells, namely “emergency granulopoiesis” in the BM of 
mice challenged with E. coli’s LPS or during mild CLP polymicrobial sepsis 
[210,212]. A previous study noted distinct patterns of cardiovascular response 
induced by E. coli’s LPS and P. aerugionsa’s LPS in rats. In particular, P. 
aeruginosa’s LPS induced higher level of serum TNF-α than E. coli’s LPS [213]. 
Therefore, the different BM response induced by E. coli’s LPS and P. 
aeruginosa’s LPS is likely due to the different microorganisms the endotoxin is 
derived from, and also to the different experiment models used. Indeed, myeloid 
expansion is observed in certain models of CLP, where the CLP procedure 
performed with a 25-gauge needle induces a milder polymicrobial sepsis [212]. In 
the current study, the colon puncture was performed using a 21G1 gauge needle 
and induced an acute and severe peritonitis. Therefore, the model I used was 
more lethal and recapitulated the stage of acute and severe sepsis characterized 
by immunoparalysis and neutropenia.   
It was previously reported that the P. aeruginosa’s LPS triggered BM 
response required intact TLR4 function. In order to further identify whether this 
response in the BM is mediated by MyD88-dependent pathway or MyD88-
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independent pathway (TRIF-dependent pathway), I compared the BM response 
of WT, MyD88-/- and TRIF-/- after LPS challenge. I observed that the 
dysfunctional expansion of HSPC and the myeloid differentiation block were 
mediated by two different pathways. LSK expansion is dependent on the TRIF-
dependent pathway whereas myelosuppression and neutropenia are dependent 
on the MyD88 pathways.  
Further characterization of the LSK fraction by the SLAM markers 
revealed that the percentage of the LT-HSC, MPP1 and MPP2 compartment 
were all increased by LPS in a TLR4/TRIF dependent manner. However, similar 
to the response to IFN-1 exposure [165], the absolute number of LT-HSC was 
not affected by LPS. Sca-1 is one of the canonical markers used to define HSC 
[125]. It is an 18-kDa mouse glycosyl phosphatidylinositol-anchored cell surface 
protein (GPI-AP) of the Ly6 gene family [214]. All HSC express Sca-1 [215,216]. 
During normal hematopoiesis, Sca-1 expression is downregulated as HSC 
differentiate into progenitors and mature blood cells [142]. However, during 
inflammation, cytokines can reactivate Sca-1 in myeloid progenitor cells 
[205,206]. A recent study by the Passegue group showed that IFN-1 exposure 
reactivates Sca-1 expression in myeloid progenitors in vitro [165]. Because the 
absolute number of LT-HSC was not increased by LPS like the LSK cells, it was 
reasonable to think that the LSK expansion in our LPS model could be due to 
Sca-1 reactivation by Sca-1-negative myeloid progenitors. To better define this 
effect, I used Lys-EGFP mice, in which only myeloid cells express the GFP 
protein, and can be tracked by flow cytometry analyses. Analysis of the GFP 
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distribution within the primitive LSK subsets revealed that while there were 
indeed a small number of the expanded LSK cells were GFP positive 
contaminating myeloid progenitors with reactivated Sca-1 expression, the 
majority of the expanded LSK cells were GFP negative. The results from the Lys-
EGFP mice showed that Sca-1 re-expression in the myeloid progenitors is not 
the main mechanism for expansion of the LSK fraction during LPS challenge. 
Next, I investigated the cell cycle activity in the LSK cells. In vivo BrdU analysis 
showed that LPS induced quiescent LSK cells to enter S-phase. This response 
requires both MyD88 and TRIF pathway to be intact. This is not surprising for the 
TRIF-/- mice but it is intriguing in the case of MyD88-/- mice, as LSK expansion 
was also observed in LPS-challenged MyD88-/- mice. Cell cycle analyses in LPS-
MyD88-/- LSK cells suggest that mechanism(s) other than cell cycle activation 
is/are involved in the LSK expansion in MyD88-/- mice. Cell pool expansion 
without cell cycle activation has been reported in other context such as Skp2-/- 
mice [217]. One possible mechanism is that symmetrical division is favored over 
asymmetrical division in the MyD88-/- LSK cells after LPS challenge. Paired-
daughter cell assay on these LSK cells is required to further test this hypothesis. 
In summary, LSK expansion during LPS is likely due to increased cell cycle 
activity in the WT mice. However, the reason why MyD88-/- LSK was expanded 
without change in the cell cycle activity remains elusive. Increased proliferation 
rate and reduced quiescence in LPS-WT LSK cells suggest they could have 
lower regenerative function and engraftment rate compared to LPS-MyD88-/- LSK 
and LPS-TRIF-/- LSK cells [153]. This aspect is further pursued in Chapter Four.   
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Our group has previously shown that bacterial sepsis induces TLR4-
mediated depletion of myeloid progenitors and neutropenia [13]. Here, I further 
identified that the myeloid differentiation block during LPS challenge or CLP 
polymicrobial sepsis requires the TLR4/MyD88-dependent signaling pathway but 
not the TLR4/TRIF-dependent pathway. Interestingly, following LPS, MyD88-/- 
mice exhibited normal number of GMP and neutrophils, but decreased CMP 
levels. Therefore, I hypothesize that LPS-induced activation of the TLR4/MyD88 
pathway blocked the egress from CMP to GMP and ultimately Gr1+/Mac1+ cells. 
This hypothesis was confirmed in in vitro differentiation assay of CMP and GMP 
from PBS- or LPS- challenged WT, MyD88-/- and TRIF-/- mice: septic WT and 
TRIF-/- CMP showed a delayed differentiation that was rescued by loss of MyD88, 
whereas LPS-GMP showed no difference compared to the PBS control and 
among the different genotypes. In summary, our in vitro data strongly suggests 
that although a reduced CMP population was observed in the MyD88-/- mice 
challenged with LPS, these CMP are functionally different from the septic WT 
and TRIF-/- CMP in the sense that they are able to egress through the myeloid 
differentiation pathway to generate GMP and neutrophils. Further transplantation 
experiments with CMP from different genotypes are necessary to consolidate this 
finding. 
Multiple in vivo and in vitro studies showed TLR ligands could impact HSC 
functions and hematopoiesis directly [218] [172]. In the CMP in vitro 
differentiation assay, I showed activation of TLR4/MyD88 pathway blocked 
myeloid differentiation in a cell-autonomous manner. Hematopoietic cells can 
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also be affected by the microenvironment mediators that are activated by TLR 
ligands. It is reported that BM mesenchymal stem cells in the BM niche express 
TLR4 and sense circulating TLR ligands to regulate monocyte migration [219]. 
Another study showed that TLR4-expressing nonhematopoietic cells in the BM 
were required for emergency myelopoiesis upon LPS stress [210]. Besides 
microenvironment cells, cytokines induced by LPS also contribute to the non-cell 
autonomous effect. Indeed, I found that LPS challenge significantly increased the 
serum level of G-CSF, TNF-α and IFNα in a Myd88-dependent manner. These 
pro-inflammatory cytokines are known for their roles in regulating hematopoiesis. 
Whether the protective effect of MyD88 deficiency on myeloid differentiation 
block is mediated by a cell-autonomous or non-cell autonomous mechanism 
remained elusive. Using a reciprocal transplantation method, I found that deletion 
of MyD88 in hematopoietic cells or in the microenvironment alone could only 
partially rescue the myeloid differentiation following LPS challenge. The in vitro 
differentiation data and in vivo chimera data shows that activation of MyD88 both 
in the myeloid cells and in the microenvironment contributes to myelosuppression 
during sepsis.  
Because activation of the TLR4/MyD88 pathway in the microenvironment 
also contributed to myeloid suppression, I proceeded to identify potential 
alterations in the BM niche following LPS challenge. Using the IVFM method, I 
showed that the BM vascular niche is significantly altered by acute LPS 
exposure. Enlarged vessels were seen in WT and TRIF-/- mice following LPS. 
Quantitative analysis of vascular permeability revealed that loss of MyD88 can 
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prevent capillary leakage induced by endotoxin. Vasodilatation and capillary 
leakage are two important pathological events during septic shock that induce 
hypotension in patients [220]. Here, I found that MyD88 deletion can prevent 
these events in the BM vasculature. Thus, the TLR4/MyD88 pathway mediates 
both myelosuppression and endothelial dysfunction following LPS. This 
observation suggests the possibility of a link between these two processes and 
thus then highlights the importance to study the interplay between the 
microenvironment and hematopoietic function in sepsis. 
While studying the functional role of TLR4/MyD88-dependent pathway in 
the BM response following LPS challenge, it is important to consider the possible 
indirect activation of MyD88-pathway by cytokines induced by inflammation, such 
as IL-1 and IL-18, as MyD88 is a downstream adaptor of their receptors 
[221,222] (Figure 3.11). Global cytokine profiling with cytokine array, however, 
showed that IL-1 levels in the serum of LPS-challenged mice in the current study 
were not significantly elevated (data not shown). Therefore, it is unlikely that IL-
1R/MyD88-signaling pathway play a role in the BM response during LPS 
challenge. Assuming that  other yet-to-be-identified cytokine(s) X induced by LPS 
stimulation were playing a major role in inducing MyD88-dependent myeloid 
suppression, a complete rescue effect of Gr1+/Mac1+ loss should have been 
observed in the MyD88-/- Donor chimera, because the production of cytokine X by 
the WT microenvironment cells after LPS challenge remained intact. However, 
my chimera data showed loss of MyD88-/- in the hematopoietic cells alone could 
only partially prevent BM neutropenia, suggesting that cytokine-activation of 
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MyD88-dependent pathway did not play a dominant role in BM neutropenia 
during LPS stimulation. However to definitively validate this point further 
experiments need to be performed to determine the impact of recombinant IL1b 
on BM and the effects of LPS challenge in mice null for the  IL1B receptor.  
In conclusion, this part of the study dissected the functional role of 
TLR4/MyD88 and TLR4/TRIF pathway in mediating the BM response during 
P.aeruginosa’s LPS challenge and CLP polymicrobial sepsis. The TLR4/TRIF 
pathway played a dominant role in mediating the LSK expansion during sepsis. 
While Sca-1 re-expression in the myeloid progenitors leads to a small fraction of 
contaminating LSK cells, the majority of expanded LSK cells are real HSPC. Cell 
cycle activity is significantly increased in septic LSK cells both in MyD88 and 
TRIF dependent manner. Loss of MyD88 significantly prevents myeloid 
differentiation block essentially at the stage of CMP and ultimately prevents 
neutropenia upon endotoxemia or sepsis. Interestingly, such protective effect 
required a complete ablation of the TLR4/MyD88 pathway both in the 
microenvironment and in the hematopoietic cells. Finally, I made a novel 
discovery that the activation of TLR4/MyD88 lead to BM vasculature niche 
damage in vivo. Collectively, my results suggest the TLR4/MyD88 signaling is a 
very good therapeutic candidate for protecting the BM from inflammatory damage 
during sepsis.  Studies involving the use of MyD88 decoy peptide are underway.  
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Figure 3.11 Signaling pathways engage with the MyD88 adaptor protein. 
MyD88 is the direct adaptor protein of TLR4, TLR2, TLR7, TLR8 and TLR9. It is 
the recruiter of IRAK4 to activate downstream signaling pathways including NF-
κB and/or p38 pathway. MyD88 is also a key adaptor molecule for IL-1R, IL-18R 
for IRAK4 recruitment and associate with IFNγR1 for p38 activation. 
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CHAPTER FOUR 
ABLATION OF THE TRIF and MYD88 PATHWAY PROTECTS HSC FUNCTION 
DURING P. AERUGINOSA’S LPS CHALLENGE 
INTRODUCTION 
Profound BM dysfunction and hematopoietic failure have been observed 
during sepsis both in human patients and in experimental animals [223-226]. 
Administrations of CD34+ HSPC greatly improved the survival rate of mice with 
polymicrobial sepsis likely by attenuating the hypoinflammatory response [227]. It 
has been reported that the regenerative potential of the LT-HSC resides mainly 
in the quiescent fraction [153]. Cell cycle activity increases as HSC differentiate 
along the hematopoietic hierarchy restricting their self-renewal activity [153]. 
Several studies have shown that chronic inflammation, LPS, IFNs or G-CSF 
exposure diminish the self-renewal and reconstitution potential of HSC while 
activate their cell cycle entry [157,162,172]. One common BM response to these 
stimuli is the expansion of the LSK fraction. Previous work by our group showed 
that the expanded LSK cells isolated from the WT mice challenged with P. 
aeruginosa’s LPS lost their engraftment and reconstitution potential in 
transplantation experiments [13].  Results from the previous chapter showed that 
LPS induced cell cycle activation in WT LSK fraction in a TLR4/MyD88 and TRIF 
dependent manner. The different cell cycle activity in septic WT LSK and MyD88-
/- LSK, TRIF-/- LSK cells suggested they may have different stem cell functions. 
Here, I found that loss of TRIF fully preserved HSC function following LPS, while 
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loss of MyD88 only partially protected HSC from endotoxic damage. 
Consistently, ablation of the TLR4/TRIF or MyD88 pathway prevented the 
irreversible downregulation of crucial transcription factors required for 
myelopoiesis and HSC functions in septic LSK cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
RESULTS 
4.1 Loss of TRIF and MyD88 rescue the long-term engraftment efficiency of HSC 
after LPS challenge. 
To determine the impact of the immunophenotypic expansion of the LSK 
pool following LPS, and the potential role of MyD88 and TRIF, we tested their 
function in HSC by performing the competitive reconstitution assay. Briefly, 2500 
CD45.2+ LSK cells containing equivalent amount of LT-HSC were sorted from the 
BM of PBS- or LPS challenged WT, MyD88-/- or TRIF-/- mice, and were 
transplanted into lethally irradiated CD45.1+ recipient mice together with 105 
competitor cells. Changes in PB chimerism were followed up to 24 weeks (Figure 
4.1 A). We found that the ability of normal (PBS) LSK to engraft at short-term and 
long-term was similar in WT, My88-/- and TRIF-/- genotypes (70-77% chimerism at 
24 weeks). MyD88-/- LSK cells showed a slight lower short-term engraftment 
efficiency which was not statistically significant. In contrast, WT, MyD88-/- and 
TRIF-/- LPS LSKs displayed great differences in their ability to compete and 
engraft at short- and long-term. The engraftment ability of LPS-WT LSK at short- 
and long-term was very poor, and chimerism was 9% at weeks 8 and 16, 
respectively, and 7% and 15% at weeks 20 and 24, respectively (Figure 4.1 B).  
The low engraftment of LPS-WT cells was not due to decreased homing (Figure 
4.1 C). Loss of TRIF greatly improved short-term engraftment (51% and 63% 
chimerism at week 8 and 16) and fully restored long-term reconstitution at 24 
weeks (68%). Interestingly, loss of MyD88 enhanced significantly short- and 
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long-term engraftment, but less robustly than TRIF deletion (35%, 48% and 58% 
chimerism, respectively at week 8, 16 and 24). 
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Figure 4.1 Loss of TRIF and MyD88 protects LSK engraftment potential. 
(A) Experimental design for LSK competitive reconstitution assay. (B) Donor 
engraftment (CD45.2+) in the PB at indicated time points in BoyJ mice 
transplanted with WT PBS-LSK (Black square solid bar; n = 6-15), MyD88-/- PBS-
LSK (Black circle solid bar; 2 weeks: n = 3; 4-24 weeks: n = 8-12), TRIF-/- PBS-
LSK (Black triangle solid bar; n = 7-8), WT LPS-LSK (Red; n = 5-14), MyD88-/- 
LPS-LSK (Purple; n = 6-12) and TRIF-/- LPS-LSK (Green; n = 7-8). (C) Mean 
percentage of CD45.2+ cells in the BM of CD45.1+ Boy/J mice 16 hours after 
receiving 25,000 LSK cells derived from PBS or LPS challenged C57BL6/J mice 
(n = 3). Data represent mean ± SEM. For (B), LPS vs. PBS: *p < 0.05, **p < 0.01, 
unpaired t test; LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, ## p < 0.01, 
unpaired t test. For (C), LPS vs. PBS: n.s, not significant, unpaired t test. 
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4.2 Increased contribution of LPS-MyD88-/- and LPS-TRIF-/- HSC to the recipient 
BM following transplantation. 
In order to further study the reconstitution capability of septic LSK in the 
BM at long-term (24 weeks), I analyzed the hematopoietic compartments in the 
recipients of WT, TRIF-/- and MyD88-/- LSK cells (septic vs. normal) at 24 weeks 
after transplantation. Consistent with the PB result, I found that only 10% of all 
BM cells were CD45.2 donor-derived in mice transplanted with LPS-WT LSK, 
whereas CD45.2 donor-derived cells represented 50%-60% of total BM when 
LPS-MyD88-/- were transplanted (Figure 4.2 A). In particular, in mice transplanted 
with TRIF-/- LSK cells, the contribution of septic LSK was similar to normal LSKs, 
indicating a complete protection. To examine the donor LSK’s capacity to 
regenerate new LSK cells in the recipients at long-term, I compared the mean 
intensity of the CD45.2-PE within the LSK population from all experimental 
groups. Sorted LPS-WT LSK cells were unable to give rise to new LSK cells in 
the recipients as shown by the dramatic left shift of the histogram peak compared 
to the control recipients that received normal LSKs. In contrast, LPS-TRIF-/- LSKs 
were able to derive new LSK cells upon transplantation. At the same time, the 
capacity of LPS-Myd88-/- LSK cells’ capacity to regenerate new LSK cells was in 
between WT and TRIF-/-, indicating a partial rescue (Figure 4.2 B). Consistent 
with the histogram data, flow cytometry analyses in the primitive subpopulations 
showed a low contribution of LPS-WT LSK to the LT-HSC, MPP1 and MPP2 
subsets (≤ 30%). Transplanted LPS-TRIF-/- LSK cells contributed more than 80% 
to all the primitive subsets. Again, loss of MyD88 in the LSK subsets after acute 
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LPS exposure could only partially maintain the contribution to LT-HSC, MPP1 
and MPP2 primitive subsets (Figure 4.2 C).  
After 24 weeks from transplant the absolute number of donor LT-HSC in 
the recipient BM was compared with the parental mice as input control. Healthy 
donor LT-HSC from WT, MyD88-/- and TRIF-/- maintained a similar regeneration 
potential. Consistent with the PB engraftment data, a dramatic decrease in LPS-
LT-HSC number was observed (5-fold). On the contrary, LPS-TRIF-/- LSK cells 
showed the capacity to generate comparable number of LT-HSC cells as the 
normal LSK cells 24 weeks after transplantation. Moreover, the absolute number 
of LPS-TRIF-/- LT-HSC in the recipients was significantly higher than the LPS-WT 
LT-HSC, while LPS-MyD88-/- LT-HSC exhibited an intermediate regeneration 
potential between LPS-WT and LPS-TRIF-/- LT-HSC (Figure 4.2 D).  
The data from the analysis of absolute number indicated that the self-
renewal potential of LPS-TRIF-/- LT-HSC was not hampered. To test this 
hypothesis, we calculated the self-renewal quotient. LT-HSC self-renewal 
capacity (self-renewal quotient) was measured as described by Challen et al. 
[228]. Total absolute number of LT-HSC at 24 weeks post-transplantation was 
established and divided by the absolute number of injected LT-HSC (Table 4.1). 
As shown in Figure 4.2, LPS-WT LT-HSC’s self-renewal was significantly 
lowered than the normal WT LT-HSC whereas the self-renewal capacity of LPS- 
TRIF-/- LT-HSC was fully maintained. Surprisingly, although the LPS-MyD88-/- 
LSK cells demonstrated a partial rescued stem cell function, the self-renewal 
quotient were comparable to the normal control and significantly higher than the 
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WT septic cells. The cellular mechanism underlying these differences requires 
further investigation. In summary, these data showed that loss of TRIF-/- can 
completely preserve the engraftment and regeneration potential of endotoxin-
challenged HSC. In other words, activation of the TLR4/TRIF pathway during 
acute inflammation significantly hampers the LT-HSC self-renewal potential.  
 
Table 4.1 Percentage of LT-HSC in LSK cells.  
 % of LT-HSC in LSK cells Cells/2500 LSK 
cells 
PBS SEM LPS SEM PBS LPS 
WT 20.5 ±0.66 8.87 ±0.91 512 211 
MyD88-/- 19.1 ±1.79 9.19 ±0.97 479 229 
TRIF-/- 15.9 ±2.46 9.09 ±0.57 397 227 
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Figure 4.2 Loss of TRIF and MyD88 provide functional protection to LPS 
challenged LSK cells. 
(A) Percentage of donor engraftment of WT, MyD88-/- and TRIF-/- PBS or LPS 
LSK cells (CD45.2+) in the BM of recipient mice at 24 weeks post-transplantation 
(n = 7-9). (B) Representative histogram of intensity of PE-CD45.2 within the LSK 
population of recipient mice (n = 7-9). (C) Percentage of donor-derived CD45.2+ 
BM LT-HSC, MPP1 and MPP2 in recipient mice (n = 7-9). (D) Absolute number 
of donor LT-HSC per femur in: Blue, normal WT, MyD88-/- and TRIF-/- mice; Red 
in mice receiving LSK cells from PBS-challenged WT, MyD88-/- and TRIF-/- mice 
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24 weeks post-transplantation; and Green, in mice receiving LSK cells from LPS-
challenged WT, MyD88-/- and TRIF-/- mice 24 weeks post-transplantation (n = 7-
9).still need to decide color. (E) Self-renewal quotients of LT-HSC cells from PBS 
and LPS challenged WT, MyD88-/- and TRIF-/- mice at 24 weeks post-
transplantation. Quotient is calculated by dividing the absolute number of LT-
HSC by the average number of LT-HSC input at the time of transplantation (n = 
7-9). (F) Number of LT-HSC was estimated based on the general percentage of 
LT-HSC within the LSK population from four independent experiments and the 
number of LSK cells used for transplantation (Table 4.1).  Data represent mean ± 
SEM. For (A), (C), and (E), LPS vs. PBS: *p < 0.05, **p < 0.01, unpaired t test; 
LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, ##p < 0.01, unpaired t test. 
For (D), LPS vs. PBS: *p < 0.05, unpaired t test; LPS-WT vs. LPS-MyD88-/- vs. 
LPS-TRIF-/-: #p < 0.05, one-way ANOVA. 
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4.3 Different impact of TRIF and MyD88 deletion on HSC multilineage 
reconstitution following endotoxic injury.  
 To determine whether acute LPS exposure altered the ability of HSC to 
contribute to multilineage progenitors, and to evaluate whether MyD88 and/or 
TRIF contribute to such function, I compared the progenitor and mature myeloid 
subsets in the BM from all the recipient mice. Flow cytometry analyses indicated 
that LPS-WT LSK contributed little to these subsets compared to the control: 
CMP (20% vs. 90%); GMP (20% vs. 90%); MEP (15% vs. 97%); CLP (25% vs. 
60%) and Gr1+ myeloid cells (5% vs. 98%). Loss of TRIF rescued the ability of 
the septic LSK cells to contribute to these subsets: 80% in CMP, GMP and MEP; 
65% to CLP and 75% to Gr1+ cells. Loss of MyD88 had some protective effect 
and increased the contribution to CMP, GMP and MEP to up to 40%; CLP up to 
25% and Gr1+ cells up to 55% (Figure 4.3 A). Analyses of multilineage 
contribution in the PB were consistent with these observations. LPS-WT HSC 
showed low contribution to myeloid, B and T cells at early and late time points 
(Figure 4.3 B, C); LPS-TRIF-/- HSC contributed robustly to all 3 lineages since the 
early time points of engraftment and MyD88 showed an intermediate behavior, 
with progressive improvement overtime (Figure 4.3 B, C). 
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Figure 4.3 Loss of TRIF protected the multilineage reconstitution ability of septic 
LSK cells.  
(A) Mean percentage of donor derived CD45.2+ BM CMP, GMP, Gr1+, MEP and 
CLP populations in recipient mice (n = 8-10). (B) Mean percentage of CD45.2+ 
PB cells in myeloid cells (Gr1+), B cells (B220+) and T cells (CD4+ or CD8+) in 
recipient mice at 8 weeks and 24 weeks post-transplantation (n = 7-16). (C) Line 
graph shows mean percentage of CD45.2+ cells in in myeloid cells (Gr1+), B cells 
(B220+) and T cells (CD4+ or CD8+) in recipient mice at indicated timepoint post-
transplantation (n = 7-16). Data represent mean ± SEM. LPS vs. PBS: *p < 0.05, 
**p < 0.01, unpaired t test; LPS-WT vs. LPS-MyD88-/- vs. LPS-TRIF-/-: #p < 0.05, 
## p < 0.01, one-way ANOVA.  
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4.4 MyD88-/- and TRIF-/- LSK cells were able to maintain the expression of 
essential regulators for myelopoiesis. 
 Evaluation of the BM response to endotoxemia in MyD88-/- and TRIF-/- 
mice revealed a distinct role of MyD88 and TRIF on myeloid progenitors and 
stem cells. To determine whether this effect was also associated with disruption 
of the transcriptional regulators, we analyzed the expression of PU.1 and 
C/EBPα, two transcription factors important for myeloid differentiation. Levels of 
PU.1 and C/EBPα expression were determined in LSK cells sorted from LPS or 
PBS-treated WT, MyD88-/- and TRIF-/- mice (Figure 4.4A).   
 PU.1 encoded by Spi1 is a transcription factor that acts upstream of 
regulators controling myelopoiesis [229,230]. qRT-PCR analyses showed a 3-fold 
decrease of PU.1 transcripts in LPS-WT LSK cells and a 2-fold decrease in the 
LPS-TRIF-/-. PU.1 gene expression level was preserved in LPS-MyD88-/- LSK 
cells (Figure 4.4 B). C/EBPα is another important transcription factor required for 
myelopoiesis, which is encoded by CEBPA [136]. qRT-PCR data showed that 
both MyD88-/- and TRIF-/- can prevent the downregulation of CEBPA induced by 
LPS, as observed in WT mice (Figure 4.4 C). Collectively, my data is in 
agreement with the knowledge that loss of MyD88 can prevent myeloid 
differentiation block during LPS stress. It suggests that loss of MyD88 can protect 
the myeloid differentiation regulatory machinery from being disrupted by LPS at 
the level of primitive HSPC.  
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Figure 4.4 LPS downregulates transcription factors essential for myeloid 
differentiation in the LSK cells in a MyD88 dependent manner. 
(A) Experiment design for gene expression analyses in normal and septic LSK 
cells from WT, MyD88-/- and TRIF-/- mice. (B) Relative mRNA level of PU.1 (Spi1) 
compared to Gapdh in sorted LSK cells (n = 3-9). (C) Relative mRNA expression 
level of CEBPA compared to Gapdh in sorted LSK cells (n = 3-9). Data represent 
mean ± SEM. LPS vs. PBS: *p < 0.05, **p < 0.01, unpaired t test; LPS-WT vs. 
LPS-MyD88-/- or LPS-TRIF-/-: #p < 0.05, unpaired t test. 
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4.5 Downregulation of essential regulators for HSC function and myelopoiesis 
persisted at 24 weeks post-transplantation.  
 Acute LPS exposure induced long-term HSC cell function damage as 
shown by the competitive repopulation assay. TRIF deficiency completely 
rescued HSC from the LPS-induced HSC injury while MyD88 deficiency had an 
intermediate protective effect. My hypothesis is that short-term endotoxin stress 
leads to a permanent alteration of HSC at the genetic level. To test this 
hypothesis, I further examine the gene expression levels of the PU.1 and 
C/EBPα transcription factors in sorted donor-derived LSK cells from recipient 
mice, at 24 weeks after transplantation (Figure 4.5 A).  
 Downregulation of PU.1 and C/EBPα was found in sorted donor-derived 
LSK from LPS-WT LSK recipients 24 weeks after transplantation, suggesting that 
these alterations are irreversible (Figure 4.5 B). On the contrary, mRNA levels of 
these molecules were either upregulated or unchanged in donor-derived LSK 
cells from LPS-MyD88-/- or LPS-TRIF-/- LSK recipients (Figure 4.5 C-D). PU.1 is 
required for maintaining the balance between HSC self-renewing division and 
quiescence [229]. Depletion of C/EBPα is associated with HSC exhaustion [231]. 
Collectively, these published results and our data suggested that acute LPS 
exposure leads to long-term irreversible downregulation of key transcription 
factors required for HSC maintenance and myelopoiesis. Loss of TRIF and/or 
MyD88 can partially, if not completely, prevent such disruption. The preservation 
of the gene expression of key transcription factors is likely to be critical for the 
protective effect of TRIF and MyD88 deficiency on HSC function. 
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Figure 4.5 LPS-induced irreversible long-term genetic alterations in the LSK 
cells. 
(A) Experiment design for gene expression comparison between normal and 
septic LSK cells after 24 weeks of transplantation. (B) Fold change of expression 
levels of PU.1 and CEBPA in parental mice and recipient mice reconstituted with 
normal or septic LSK cells (n = 3-4). Data represent mean ± SEM. LPS vs. PBS: 
*p < 0.05, **p < 0.01, unpaired t test; LPS-WT vs. LPS-MyD88-/- or LPS-TRIF-/-: 
#p<0.05, unpaired t test.   
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CONCLUSION AND DISCUSSION 
How inflammation affects HSC function has been an intriguing question 
that still lacks a comprehensive answer. A few studies revealed that acute or 
chronic infection greatly impairs the short- and long-term engraftment potential of 
HSC following transplantation [157,172]. The discovery that TLR4 is expressed 
by HSPC provides the molecular evidence that HSPC participate directly in the 
primary BM response to infections [171]. LSK cells from mice challenged with P. 
aeruginosa’s LPS were unable to engraft after transplantation into lethally 
irradiated mice [13]. Functional damage of the HSPC by P. aerugionosa’s LPS is 
associated with myeloid differentiation block and neutropenia, which are 
dependent on the TLR4 pathway. In the previous chapter, I have shown that 
activation of TLR4/MyD88 signaling leads to myeloid suppression in the BM. In 
the current chapter, I further dissected the contribution of TLR4/MyD88 and 
TLR4/TRIF signaling in mediating HSC injury after acute exposure to LPS.  
In vivo BrdU analysis showed that P. aeruginosa’s LPS activated 
quiescent LSK cells and forced them into cell cycle. Loss of MyD88 or TRIF 
prevented cell cycle activation of LSK cells (Figure 3.3). Previous studies showed 
that actively proliferating HSC lose their post-transplantation engraftment 
capacity and that HSC’s self-renewal and multilineage potential resides mainly in 
the quiescent fraction [153]. The different cell cycle dynamics of the LSK cells 
from septic WT, MyD88-/- and TRIF-/- mice suggest that they exhibit different stem 
cell functions when transplanted into lethally irradiated recipients. Indeed, in the 
competitive reconstitution assay, WT septic LSK cells’ engraftment potential was 
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very low at short- and long-term. Since loss of MyD88 was able to preserve 
mature myeloid cell development in the BM, I expected the LPS-MyD88-/- LSK 
cells were also functionally protected. However, LPS-MyD88-/- LSK cells were 
only partially rescued, but their low engraftment activity at short-term was 
gradually improved at long-term. LPS-MyD88-/- LSK also displayed a partial 
protective effect in the multilineage regenerative potential. The regenerative 
function of LSK cells from septic TRIF-/- mice was significantly preserved 
compared to WT and MyD88-/-. Similarly, when the BM compartments of different 
recipients were examined 24 weeks after transplantation, I observed that the 
LPS-WT LSK cells have a rather poor reconstitution capacity in regenerating any 
subset in the BM. This is consistent with the finding that LT-HSC exhaustion is 
observed in LPS-WT LSK cell recipients. Similar to the peripheral blood data, 
LPS-TRIF-/- LSK cells displayed the same capacity in generating primitive HSPC 
subsets and mature myeloid cells as the normal LSK cells. In fact, loss of TRIF 
prevented LT-HSC exhaustion in septic LSK cells after transplantation. In 
contrast, LPS-MyD88-/- LSK cells did not show advantageous contribution to the 
primitive LT-HSC and could only partially preserve the ability to regenerate 
myeloid progenitors and mature myeloid cells. The fact that MyD88-/- partially 
prevented LPS-induced LT-HSC exhaustion at 24 weeks after transplantation 
suggested that LPS-MyD88-/- LSK cells are slowly “recovering” from the damage 
induced by acute LPS exposure. This hypothesis requires a secondary 
transplantation experiment to be confirmed. The finding that TRIF deletion fails to 
prevent myeloid suppression after acute LPS exposure, but protects HSC from 
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injury, indicates that TLR4/TRIF signaling has a different immediate impact on 
these two cell types (myeloid progenitors and HSC) and that these two effects 
are independent. This point is further re-enforced by the observation that 
following LPS challenge, MyD88 has a dominant protective effect on myeloid 
progenitors’ differentiation function, but only a mild protective effect on HSPC 
functions following LPS challenge. In summary, LPS-induced TLR4/TRIF 
activation mainly affects HSC’s stem cell function while TLR4/MyD88 activation is 
the major mediator of myelosuppression.  
Unlike MyD88, which is a common adaptor for all TLR signaling except for 
TLR3, TRIF participates in the signal transduction of TLR3 and TLR4 [78]. The 
TLR4/TRIF signaling leads to type I interferon production via IRF-3 activation 
[103]. TRIF function has been intensively studied in immune response in different 
infection scenarios. Hematopoietic TRIF activity was found to be crucial for 
bacterial clearance and survival in a model of murine gram-negative pneumonia. 
Interestingly, in the same study, hematopoietic TRIF expression significantly 
contributed to cellular injury during late-stage of infection [209]. Upon TLR4 
ligation by LPS, TRIF is involved in macrophage inflammatory cytokine 
production and dendritic cell activation [103,232]. While TRIF function is 
extensively studied in mature immune cells, how it affects the primitive 
hematopoietic subsets has remained largely unknown. In a recent study, the 
TLR4/TRIF pathway significantly contributed to allogeneic BM cell rejection by 
mediating the production of pro-inflammatory cytokines by macrophages and NK 
cells [233]. The result from this study was in agreement with my finding that 
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TRIF-/- could protect BM cell engraftment activity upon inflammation. However, 
since the transplantation was performed using whole BM cells, the scope of this 
study was limited, failing to provide knowledge specific of HSC function. The 
observation that TRIF-/- septic LSK cells displayed protected short-term and long-
term engraftment potential and multilineage regenerative activity both in the 
peripheral blood and BM could be explained by two different mechanisms. The 
first was that in TRIF-/- mice, the lack of TRIF-mediated production of pro-
inflammatory cytokines including Type I IFN by resident and/or mature immune 
cells induced by LPS prevented the damage to HSC. Another scenario was that 
the lack of TRIF-/- directly prevented the activation of TLR4/TRIF signaling 
pathway in the HSPC induced by LPS ligation, hence preventing the LPS 
damage. To address this question, it will be of great importance to use the model 
of TRIF-/- chimera with TRIF loss of function only in the BM microenvironment or 
in the hematopoietic cells, and then examine how LPS affects the HSC function 
of these chimeras post-transplantation. Although this open question remains to 
be studied, my findings provide the evidence that TLR4/TRIF signaling plays a 
dominant role in mediating HSC damage induced by endotoxemia.  
Because acute LPS exposure leads to a prolong impairment in WT HSC 
function even when they are transplanted into a healthy microenvironment, I 
hypothesize that permanent alterations in these HSC must have occurred. First, I 
determined whether the gene expressions of transcriptional factors were affected 
in the LSK fractions following LPS exposure. PU.1 and C/EBPα were selected for 
preliminary study because they were required for both myeloid cell differentiation 
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and HSC self-renewal maintenance. Dramatic downregulation of both 
transcription factors was found in WT septic LSK cells. This alteration persisted 
when septic LSK cells were isolated from recipients 24 weeks after 
transplantation, confirming the hypothesis that irreversible alteration in the 
genetic level indeed occurs in response to LPS challenge. Both loss of MyD88 
and TRIF were able to maintain the expression levels of C/EBPα in parental 
animals or after transplantation. Interestingly, PU.1 was downregulated in LSK 
cells sorted from LPS challenged TRIF-/- mice but unaltered PU.1 expression was 
observed in septic TRIF-/- LSK cells 24 weeks after transplantation. I hypothesize 
that in the absence of TRIF-/-, the transient downregulation of PU.1 by acute LPS 
challenge returns to normal level after transplantation. In conclusion, acute LPS 
exposure significantly and likely permanently disrupts the gene profile required 
for normal myelopoiesis and HSC function maintenance. Future studies from our 
group are ongoing to address the role of epigenetic regulation of HSC following 
sepsis. 
Collectively, all our data show that loss of MyD88 and TRIF have 
beneficial impact on the BM during severe sepsis. However, it is of great 
importance to bear in mind that MyD88 and TRIF are necessary for the innate 
immune cells to respond to infection. Human and mice with MyD88 or TRIF 
deficiency are highly susceptible to infections [209,234]. Therefore, normal 
function of the MyD88 and TRIF is required for defending pathogens. It is only 
when these pathways go awry in conditions like hyperinflammation or sepsis that 
they confer damage effects to tissues including the BM. Although blocking the 
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TRIF and MyD88 signaling pathway seems a tempting therapeutic strategy to 
prevent BM damage during sepsis, one would reach higher level of specificity 
and safety by targeting their downstream molecules.  
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CHAPTER FIVE  
FUNCTIONAL ROLE OF MIR-21 IN LPS-INDUCED DYSFUNCTIONAL 
HEMATOPOIESIS 
INTRODUCTION 
miRNA are double-stranded non-coding RNA molecules of 19-24 nt. They 
control gene expression post-transcriptionally by binding to the 3’-UTR of target 
mRNA sequences [235]. Each miRNA potentially has a broad influence over 
several diverse genetic pathways [235]. Emerging studies showed that miRNA 
played a delicate regulatory function in HSC differentiation in the bone as well as 
in mature hematopoietic cells that constituted the immune system. miRNA 
expression and function can be regulated at three levels, from transcription, 
processing and subcellular localization, and each of these step can be influenced 
by inflammation and stress [236]. Importantly, it has been reported that activated 
TLR signaling regulates various miRNA including miR-21, miR-155, miR-146a 
and miR-9 [236]. Moreover, several miRNA have been found to be upregulated in 
the serum of patients with severe sepsis [237,238]. 
In this study, I focused on miR-21, as I found that its expression is MyD88-
dependent. Since its discovery, miR-21 has been known as an onco-mir due to 
its overexpression in multiple types of solid tumor and leukemia [239]. In a 
clinical study, miR-21 was found to have increased expression level in the 
skeletal biopsy tissue of septic patients compared to normal individuals [187]. 
miR-21 is also involved in normal immune cell differentiation during 
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hematopoiesis. Overexpression of miR-21 together with miR-196b in BM lineage-
depleted cells blocked granulopoiesis in vitro [240]. Previous work by F.J. 
Sheedy et al. revealed that miR-21 was induced via TLR4/MyD88-NF-κB 
pathway in human peripheral blood mononuclear cells upon LPS challenge; they 
further showed one of the major miR-21 targets, the tumor suppressor gene 
programmed cell death 4 (PDCD4), finely tuned the production of pro-
inflammatory factors [191]. Study of the promoter region of pri-miR-21 revealed a 
conserved binding site for AP-1, which can be activated by TLR4/MyD88 
pathway [241]. Taken together, all these results support the hypothesis that miR-
21 could be regulated by the TLR4 signaling and that it plays a role in the 
immune response to sepsis.  
The aim of this chapter was to investigate the functional role of miR-21 in 
mediating the dysfunctional hematopoietic response in the BM after LPS 
exposure. 
 
 
 
 
 
 
 
106 
 
RESULTS 
5.1 miR-21 is differentially expressed in the BM hematopoietic subsets.  
To determine the basal expression level of miR-21 in different 
hematopoietic BM subsets, I investigated the level of mature miR-21 in sorted 
LSK, CMP, GMP, MEP, Gr1+/Mac1+ cells, T cells and B cells from the BM by 
qRT-PCR. I observed that miR-21 was differentially expressed in these subsets, 
with higher expression of miR-21 was observed in the more mature subsets 
(Gr1+/Mac1+, T cells, B cells) whereas immature progenitors (CMP, GMP) and 
stem cells (LSK) showed lower levels (Figure 5.1 A). Consistent with this result, 
miR-21 expression was upregulated as immature progenitors (Lin- cells) 
progressed toward myeloid differentiation into Gr1+/Mac1+ cells in vitro (Figure 
5.1 B, C). 
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Figure 5.1 miR-21 is differentially expressed in different hematopoietic 
populations and during myeloid differentiation. 
(A) miR-21 expression levels in sorted LSK, CMP, GMP, Gr1+/Mac1+, T cell and 
B cells. (B) Average percentage of Gr1+/Mac+ cells in culture during Lin- 
differentiation assay. (C) miR-21 expression level upon Lin- cells differentiating 
into myeloid cells (n = 3). Data represent mean ± SEM. 
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5.2 P. aeruginosa’s LPS upregulates miR-21 in the LSK cells in a MyD88-
dependent manner.  
 Under homeostatic conditions, miR-21 expression in the LSK cells is low. 
Previous research has shown miR-21 induction by LPS through activation of the 
TLR4 pathway [191]. To determine whether miR-21 level in HSPC was affected 
by LPS challenge, I sorted LSK cells from LPS- or PBS-challenged WT mice. 
qRT-PCR analysis revealed a 4-fold increase in the level of mature miR-21 in 
septic LSK cells (Figure 5.2 A).  
Interestingly, such elevation was absent in TLR4-/- mice and MyD88-/- mice 
(Figure 5.2 B-C), indicating that the upregulation of miR-21 in LSK cells was 
mediated by the TLR4/MyD88-dependent pathway.   
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Figure 5.2 LPS-induced miR-21 upregulation in the LSK cells in a TLR4/MyD88 
dependent manner.  
(A) miR-21 was upregulated in LSK cells after LPS challenge for 24 hours (n = 
4). (B) miR-21 was not upregulated in LSK cells from TLR4-/- animals challenged 
with LPS (n = 2, error bar indicates standard deviation). (C) miR-21 was not 
upregulated in LSK cells from MyD88 KO animals challenged with LPS (n = 4). 
Data represent mean ± SEM, *p < 0.05, unpaired t test. 
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5.3 Development of tissue-specific miR-21 deletion mouse model. 
Because the upregulation of miR-21 was mediated in a TLR4/MyD88 
dependent manner and miR-21 played a crucial role in regulating the 
inflammatory circuit [192], I sought to determine whether miR-21 played a 
dominant role in the BM myeloid suppression induced by P. aeruginosa’s LPS. 
To this end, I generated mice with specific miR-21 deletion in the hematopoietic 
and stromal cells by crossing the Mx1-Cre mice with miR-21flox/flox mice (Figure 
5.3 A). Mx1-Cre+miR-21flox/flox and Mx1-Cre-miR-21flox/flox mice were identified by 
genomic DNA PCR (Figure 5.3 B) and subject to Poly (I:C) (pIpC) injection to 
induce specific miR-21 deletion. Mx1 promoter is active specifically in BM 
hematopoietic and non-hematopoietic cells and is activated by IFNα, induced by 
pIpC injection (Figure 5.3C). qRT-PCR analyses on the BM cells isolated from 
induced-miR-21-/- mice showed greater than 90% deletion of the miRNA (Figure 
5.3 D).    
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Figure 5.3 Generation of transgenic mice with inducible miR-21 deletion specific 
in the hematopoietic and stroma cells. 
(A) Diagram shows the crossing strategy to develop Mx1-Cre+miR-21flox/flox and 
Mx1-Cre-miR-21flox/flox mice. (B) Genotype PCR band for flox allele or wt allele 
and Mx1-Cre+ or Mx1-Cre- band. (C) Diagram shows the induction strategy. (D) 
miR-21 Taqman qRT-PCR validation of loss of miR-21 expression in Mx1-
Cre+miR-21flox/flox mice induced with pIpC.  
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5.4 miR-21 is dispensable for the BM response to endotoxemia. 
To determine whether miR-21 plays a role in MyD88 mediated 
myelosuppression, I challenged miR-21-/- mice and litter mate WT control with 
LPS. If miR-21 was critical in the process we would expect to observe a rescue 
of myeloid cells in its absence. However, loss of miR-21 had no impact on the 
hematopoietic response induced by P. aeruginosa’s LPS (Figure 5.4 A). 
Surprisingly, I noticed a slight but significant increase in the percentage of LT-
HSC in miR-21-/- mice. However, sorted expanded LT-HSC showed no significant 
advantage in hematopoietic reconstitution upon transplantation short-term and 
long-term (Figure 5.4 B-C). 
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Figure 5.4 Loss of miR-21 did not affect the BM response induced by LPS. 
(A) Bar graphs show average percentage of LSK, LT-HSC, MPP1, MPP2, CMP, 
GMP, MEP, CLP in Lin- cells and Gr1+/Mac1+ cells in total BM cells from WT and 
miR-21-/- mice challenged with PBS or LPS (n = 6-7). (B) Bar graph shows 
average percentage of LT-HSC cells in Lin- cells from WT and miR-21-/- mice 
under homeostatic conditions (n = 7). (C) Average percentage of donor-derived 
PB cells is shown in recipients of WT and miR-21-/- LSK cells (n=5). Data 
represent mean ± SEM, *p < 0.05, unpaired t test.    
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CONCLUSIONS AND DISCUSSION  
Results from this chapter demonstrated that miR-21 was upregulated 
during myeloid differentiation in homeostatic conditions. However, miR-21 
depletion in the BM did not cause obvious hematopoietic defects. Loss of miR-21 
led to a mild increased in the LT-HSC, yet how this functionally affected the LT-
HSC function remained to be determined. Although miR-21 was upregulated in 
the LSK cells by LPS in a TLR4/MyD88-dependent manner, it did not play a 
dominant role in contributing to hematopoietic dysfunction or to 
myelosuppression during acute LPS exposure. This negative result reflects the 
molecular mechanism underlying the myeloid suppression as far more 
complicated than I expected and targeting one single molecule will likely 
insufficient to prevent neutropenia. In a recent review, it has been suggested that 
miR-21 upregulation by pro-inflammatory stimulus was involve in a negative 
regulatory loop where miR-21 targeted pro-inflammatory mediators to tune down 
the inflammatory response during late stage of infection so that the amplified 
response could be resolute [192]. This could explain why deletion of miR-21 did 
not confer protective effects to the BM upon LPS challenge. However, the reason 
why loss of miR-21 did not worsen the condition remains to be determined.  
In summary, miR-21 does not seem to exert a dominant regulatory role in 
BM response during acute inflammation induced by P. aeruginosa’s LPS. Further 
studies are required to identify the functional role of miR-21 during sepsis.  
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CHAPTER SIX 
FUTURE DIRECTIONS 
In the current project, I found that loss of MyD88 prevented myeloid 
differentiation block and neutropenia during sepsis. This is of great clinical 
importance because modulation of the MyD88 pathway could confer protective 
effects to sepsis patients that develop neutropenia. However, because the 
TLR4/MyD88 pathway is required for innate immune response, targeting the 
MyD88 adapter protein itself may not be an ideal therapeutic approach. 
Therefore, the future directions of this study include identifying the downstream 
molecules involved in myeloid suppression. In Chapter Four, the mRNA levels of 
two myeloid differentiation regulators (PU.1 and C/EBPα) were found to be 
significantly downregulated in HSPC by LPS and were greatly preserved when 
MyD88 was absent. It will be interesting to determine whether overexpression of 
PU.1 or C/EBPα in mouse will bypass the myeloid differentiation defects during 
LPS challenge. The molecular link between MyD88 pathway and PU.1 and 
C/EBPα downregulation remains elusive and require further investigations. 
Reciprocal transplantation assays between WT and MyD88-/- mice showed 
that loss of MyD88 in the BM microenvironment could partially rescue the loss of 
mature myeloid cells. Consistently, loss of MyD88-/- can protect the BM 
vasculature from undergoing pathological alterations characterized by dilated 
vessels and increased leakage during LPS induction. The influence of the BM 
microenvironment on hematopoiesis is well recognized [242-245]. Preserved BM 
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vasculature in the MyD88-/- might be functionally linked to the hematopoietic 
protection. To examine this hypothesis, we would generate an endothelial cell-
specific MyD88 knock-out mouse model and compare their BM response to WT 
and MyD88-/- mice during LPS challenge. 
 Another focus of this project was to identify how the TLR4 signaling 
contributed to HSC injury during endotoxin challenge. Here, using the 
competitive reconstitution assay, I showed for the first time that loss of TRIF-/- in 
the HSPC completely preserved their long-term and short-term multilineage 
engraftment potentials. Activation of the TRIF pathway on HSPC is the major 
contributor to HSPC injury upon TLR4 activation. This finding is not only 
important for sepsis pathology but it also provides insights to our understanding 
of BM engraftment following irradiation. To move this finding forward, we will 
continue to investigate which molecule(s) downstream of TLR4/TRIF is/are 
responsible for HSC injury upon inflammation. BM failure is commonly found in 
sepsis survivors and BM failure is largely due to defective HSC function. A 
complete elucidation of how TLR4/TRIF signaling pathway contributes to HSC 
injury could provide future therapeutic opportunities to prevent BM failure in 
sepsis survivors. The discovery that loss of TRIF prevents HSC injury during 
inflammation has potential clinical implication in other medical scenarios such as 
BM transplantation and graft-versus host disease. Inflammation induced by 
irradiation often accompanies patients undergoing BM transplantation. Since the 
TRIF-signaling is involved in inflammation, modulation of the TRIF pathway could 
provide a putative therapeutic strategy to improve BM engraftment and/or 
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reducing the possible development of graft-versus-host disease following BM 
transplantation.  
 The findings outlines in this thesis are also potentially relevant for cancer 
research. Chronic inflammation is found to predispose tissues or cells to become 
pre-cancerous [246]. Increased TLR4 activation is observed in tissue samples 
from patients with liver, head and neck, ovarian and breast cancer [247] and 
constitutive activation of TLR4 promotes tumorigenesis [248]. In this project, I 
find that activation of the TLR4/MyD88 and TLR4/TRIF signaling pathway 
disrupts normal hematopoiesis in the BM and induces HSC exhaustions, which  
are often associated with leukemia pathogenesis [249]. Therefore, it will be 
important to further characterize the role of TLR4/TRIF and/or TLR4/MyD88 
activation in favoring a pre-leukemia state in HSPC.  
Finally, although loss of miR-21 confers no significant protective effects on 
LPS-induced BM injury, it is established that miR-21 is significantly elevated 
during inflammation. Therefore, this miRNA could be a good putative diagnostic 
biomarker for sepsis. Besides an inflammatory regulator, miR-21 is also a well-
characterized onco-miR that contributes to colon carcinoma and B cell lymphoma 
[250,251]. Association between chronic inflammation and cancer development 
has long been appreciated [252], and it has been shown that chronic 
inflammation contributes to tumor development [139]. Therefore, further pursuit 
of the functional role of miR-21 would also include determining whether 
prolonged upregulation of miR-21 induced by endotoxin or chronic inflammation 
will contribute to hematological malignancies.  
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To summarize, my project successfully dissected the various contribution 
of TLR4/MyD88 and TLR4/TRIF pathway in two different yet related 
hematopoietic responses in the BM during acute inflammation induced by 
exposure to high dose of P. aeruginosa’s LPS or severe polymicrobial sepsis. 
TLR4/MyD88 activation plays a dominant role in myeloid suppression and 
neutropenia but has limited impact on HSPC stem cell function. On the other 
hand, TLR4/TRIF signaling pathway significantly damages the engraftment and 
multilineage potentials of HSC upon acute inflammation (Figure 6.1). Taken 
together, my overall goal is to help gain a better understanding on the BM 
pathological alterations during sepsis and help move forward the long and 
difficult journey to tackle this complicated disease while leading to novel 
therapeutic approaches.  
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Figure 6.1 Summary of final conclusion. 
Diagram show the distinct contribution of TLR4/MyD88 and TLR4/TRIF pathway 
to hematopoietic responses in the BM during LPS challenge. (LT-HSC, Long-
term hematopoietic stem cells; MPP, Multipotent progenitors; CLP, Common 
lymphoid progenitors; CMP, Common myeloid progenitors; MEP, Megakaryocyte 
erythroid progenitors; GMP, Granulocytic monocytic progenitors; B, B cells; T, T 
cells; Ery, Erythrocytes; NE, Neutrophils; Mϕ, Macrophages). 
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